Lopinavir/Ritonavir
A Review of its Use in the Management of HIV Infection

Risto S. Cvetkovic and Karen L. Goa
Adis International Limited, Auckland, New Zealand

Data Selection

Sources: Medical literature published in any language since 1980 on lopinavir/ritonavir, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: Medline search terms were 'lopinavir and ritonavir'. EMBASE search terms were 'lopinavir and ritonavir'. AdisBase search terms were 'lopinavir-ritonavir'. Searches were last updated 7 March 2003.

Selection: Studies in patients with HIV-1 infection who received lopinavir/ritonavir coformulation. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: lopinavir/ritonavir, coformulation, HIV-1, AIDS, adults, children, pharmacodynamics, pharmacokinetics, therapeutic use.

Contents

Summary .......................................................................................... 770
1. Introduction .............................................................................. 775
2. Overview of Pharmacodynamic Properties ................................. 776
   2.1 Mechanism of Action .......................................................... 776
   2.2 Antiretroviral Activity ....................................................... 776
      2.2.1 In Vitro .................................................................... 776
      2.2.2 In Vivo .................................................................... 776
   2.3 Resistance ......................................................................... 777
      2.3.1 In Antiretroviral Therapy-Naive Patients ......................... 777
      2.3.2 In Protease Inhibitor (PI)-Experienced, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Naive Patients .................. 777
      2.3.3 In PI- and NNRTI-Experienced Patients ......................... 777
      2.3.4 In Children with HIV-1 Infection .................................. 778
3. Overview of Pharmacokinetic Properties ................................... 778
   3.1 Absorption ....................................................................... 778
      3.1.1 Effects of Food on Oral Absorption ................................ 779
   3.2 Distribution ...................................................................... 779
   3.3 Metabolism ...................................................................... 779
   3.4 Elimination ...................................................................... 780
   3.5 In Special Patient Populations .......................................... 780
      3.5.1 In Children ............................................................. 780
Lopinavir is a novel protease inhibitor (PI) developed from ritonavir. Coadministration with low-dose ritonavir significantly improves the pharmacokinetic properties and hence the activity of lopinavir against HIV-1 protease. Coformulated lopinavir/ritonavir was developed for ease of administration and to ensure both drugs are taken together, as part of combination therapy with other antiretroviral agents.

Coformulated lopinavir/ritonavir-based regimens provide adequate and durable suppression of viral load and sustained improvements in CD4+ cell counts, as demonstrated in randomised trials in antiretroviral therapy-naive and -experienced adults and children. To date, development of primary resistance to lopinavir/ritonavir has not been observed in 470 antiretroviral therapy-naive patients treated for >48 weeks. The lopinavir/ritonavir-based regimen was more effective than nelfinavir in antiretroviral therapy-naive HIV-1-infected patients in a phase III trial. The coformulation is also effective as 'salvage' therapy, as shown by low cross-resistance rates in patients who failed to respond to treatment with other PIs in phase II trials.

Coformulated lopinavir/ritonavir was well tolerated in both antiretroviral therapy-naive and -experienced HIV-1-infected adults and children with low rates of study drug-related treatment discontinuations. The most common adverse event in adults associated with lopinavir/ritonavir was diarrhoea, followed by other gastrointestinal disturbances, asthenia, headache and skin rash. The incidence of moderate-to-severe adverse events in children was low, skin rash being the most common. Changes in body fat composition occurred with equal frequency in lopinavir/ritonavir- and nelfinavir-treated naive patients, through week 60 in a phase III study. Although laboratory abnormalities occurred with similar frequency in both treatment groups, triglycerides grade 3/4 elevations were significantly more frequent with lopinavir/ritonavir. Total cholesterol and triglycerides grade 3/4 elevations appear to occur more frequently in PI-experienced than in PI-naive lopinavir/ritonavir-treated patients.

A number of clinically important drug interactions have been reported with lopinavir/ritonavir necessitating dosage adjustments of lopinavir/ritonavir and/or the interacting drugs, and several other drugs are contraindicated in patients receiving the coformulation.
Conclusion: Coformulated lopinavir/ritonavir is a novel PI that, in combination with other antiretroviral agents, suppresses plasma viral load and enhances immunological status in therapy-naive and -experienced patients with HIV-1 infection. Lopinavir/ritonavir appears more effective than nelfinavir in ‘naive’ patients and is also suitable for ‘salvage’ therapy, because of its high barrier to development of resistance. Given its clinical efficacy, a tolerability profile in keeping with this class of drugs, favourable resistance profile and easy-to-adhere-to administration regimen, coformulated lopinavir/ritonavir should be regarded as a first-line option when including a PI in the management of HIV-1 infection.

Lopinavir/ritonavir is a coformulation of two structurally related protease inhibitor (PI) antiretroviral agents. Lopinavir is a highly potent and selective inhibitor of the HIV type 1 (HIV-1) protease, an essential enzyme for production of mature, infective virus. It acts by arresting maturation of HIV-1 thereby blocking its infectivity. Thus, the main antiviral action of lopinavir is to prevent subsequent infections of susceptible cells; it has no effect on cells with already integrated viral DNA. Lopinavir has an ≈10-fold higher in vitro activity against both wild-type and mutant HIV-1 proteases than ritonavir; however, its in vivo activity is greatly attenuated by a high first-pass hepatic metabolism. The low-dose ritonavir coadministered with lopinavir inhibits metabolic inactivation of lopinavir and acts only as its pharmacokinetic enhancer. Therefore, the antiretroviral activity of coformulated lopinavir/ritonavir 400/100mg twice daily is derived solely from lopinavir plasma concentrations. Combining lopinavir with low-dose ritonavir produces lopinavir concentrations far exceeding those needed to suppress 50% of in vitro and in vivo viral replication in CD4+ cells and monocyte/macrophages (main human reservoirs of HIV-1 infection).

Thus far, no resistance to lopinavir has been detected in clinical trials in antiretroviral therapy-naive patients treated for up to 204 weeks and only 12% of HIV-1 strains from patients in whom prior treatment with multiple PIs have failed, have been observed to develop resistance to coformulated lopinavir/ritonavir. A strong negative correlation was found between the number of PI mutations at baseline and the viral response rates achieved with lopinavir/ritonavir-based regimens in PI-experienced patients, indicating that resistance to lopinavir increases with increasing number of PI mutations and that five PI mutations represent the clinically relevant genotypic breakpoint for lopinavir.

The absolute bioavailability of lopinavir coformulated with ritonavir in humans has not yet been established. Multiple-dosage absorption pharmacokinetics of lopinavir/ritonavir 400/100mg twice daily (the mean peak $[C_{\text{max}}]$ and trough $[C_{\text{trough}}]$ plasma concentrations at steady-state and the 12-hour area under the plasma concentration-time curve $[\text{AUC}_{12}]$ of either drug) were stable in antiretroviral therapy-naive and single PI-experienced adult patients receiving therapy over a 24-week evaluation period. The $C_{\text{trough}}$ values of lopinavir, achieved with lopinavir/ritonavir 400/100mg twice daily, were median 84-fold higher than the protein binding-adjusted 50% effective concentration $[\text{EC}_{50}]$ of lopinavir against wild-type HIV-1 in antiretroviral therapy-naive HIV-1-infected patients in a phase II study.

Bioavailability of lopinavir administered in either the capsule or the liquid lopinavir/ritonavir formulation can be increased substantially with concurrent ingestion of food with moderate-to-high fat content. At steady state, lopinavir is ≈98–99% plasma protein bound and the percentage of its unbound (i.e. pharmacologically active) fraction is dependent on total drug plasma concentration. Both lopinavir and ritonavir penetrate poorly into the human genital tracts and the cerebrospinal fluid.
Both agents undergo extensive and rapid first-pass metabolism by hepatic cytochrome P450 (CYP) 3A4 isoenzyme. However, ritonavir also potently inhibits this enzyme and acts as a pharmacokinetic enhancer of lopinavir. The elimination half-life and apparent oral clearance of lopinavir average ≈4–6 hours and ≈6–7 L/h, respectively, with lopinavir/ritonavir 400/100mg twice daily administration. Less than 3% and 20% of the lopinavir dose is excreted unchanged in the urine and faeces, respectively. Limited data show similar pharmacokinetics of lopinavir in children as in adults.

**Drug Interactions**

Coformulated lopinavir/ritonavir has the potential to interact with wide variety of drugs via several mechanisms, mostly involving the CYP enzymes. Coadministration of lopinavir/ritonavir is contraindicated with certain drugs (i.e. flecainide, propafenone, astemizole, terfenadine, ergot derivatives, cisapride, pimozide, midazolam and triazolam) that are highly dependent on CYP3A or CYP2D6 for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. Coadministration with lopinavir/ritonavir is also not recommended for drugs or herbal products (i.e. rifampicin [rifampin] and St. John’s wort [Hypericum perforatum]) that may substantially reduce lopinavir plasma concentrations, or drugs whose plasma concentrations elevated by the coformulation may lead to serious adverse reactions (i.e. simvastatin and lovastatin). However, a recent study in healthy volunteers suggests that adequate lopinavir concentrations may be achieved during rifampicin coadministration by increasing the twice-daily dosage of lopinavir/ritonavir in conjunction with therapeutic drug monitoring. The liquid (but not the capsule) formulation of lopinavir/ritonavir contains 42.4% ethanol (v/v) and should not be coadministered with drugs capable of producing disulfiram-like reactions (e.g. disulfiram, metronidazole).

Coadministration with saquinavir or indinavir requires no dosage adjustment, whereas coadministration with amprenavir, nevirapine or efavirenz requires a dosage increase of the coformulation typically by 33%. As the oral bioavailability of both didanosine and lopinavir/ritonavir is significantly affected by concurrent food ingestion, didanosine should be administered 1 hour before or 2 hours after lopinavir/ritonavir has been taken with food. Interactions between lopinavir/ritonavir and other nucleoside reverse transcriptase inhibitors (NRTIs) are not expected.

The coformulation is also likely to increase plasma concentrations of non-an ti retroviral drugs metabolised through the CYP3A pathway. To reduce the risk of their toxicity when coadministered with lopinavir/ritonavir, the recommended actions include: (i) monitoring of the drug plasma concentration (antiarrhythmics and immunosuppressants) or the international normalised ratio (warfarin); (ii) the use of alternative treatment (atorvastatin) or birth control methods (ethinyloestradiol); and (iii) dosage adjustment (clarithromycin [only in patients with renal failure], rifabutin, dihydroartiemide calcium-channel blockers, atorvastatin, ketoconazole and itraconazole). Coadministration of lopinavir/ritonavir 400/100mg twice daily significantly reduces the $C_{\text{max}}$ and AUC of methadone but does not appear to precipitate opioid withdrawal symptoms or require methadone dosage adjustment and could be useful in treatment of HIV-1-infected patients who are users of illicit intravenous narcotics. Drugs that induce CYP3A-mediated clearance of lopinavir and lower its plasma concentration should be used with caution (corticosteroids) or with dosage adjustment of lopinavir/ritonavir (carbamazepine, phenytoin and barbiturates) when coadministered with it.

No clinically significant interactions were observed during coadministration of norethindrone or pravastatin with lopinavir/ritonavir. Likewise, coadministration of rifabutin or ketoconazole does not require lopinavir/ritonavir dosage...
adjustment. Clinically significant interactions are not expected between lopinavir/ritonavir and either fluvastatin, dapsone, cotrimoxazole, azithromycin, erythromycin or fluconazole.

**Therapeutic Efficacy**

The therapeutic efficacy of lopinavir/ritonavir in combination with other antiretroviral agents has been evaluated in several (both comparative and noncomparative) phase II/III clinical trials in antiretroviral therapy-naive and -experienced adults and children, and in two large (>11,000 participants) prospective, nonblind, noncomparative ‘salvage’ programmes in adults with HIV-1 infection. All trials used decreasing plasma HIV-1 RNA levels (viral load) and increasing CD4+ cell counts as surrogate markers of clinical drug efficacy. The effects of lopinavir/ritonavir on HIV-1- and AIDS-related morbidity and mortality are yet to be established.

Lopinavir coformulated with ritonavir in three different dose combinations (200/100mg, 400/100mg and 400/200mg) administered twice daily in combination with standard dosages of the two commonly used NRTIs (lamivudine and stavudine) induced a rapid decline in plasma HIV-1 RNA levels that was sustained throughout the 48-week study period (the mean reduction from baseline was 2.23 log_{10} copies/mL) in a phase II trial in 100 antiretroviral therapy-naive patients. In the nonblind extension of this study, lopinavir/ritonavir 400/100mg twice daily produced continued suppression of viral load <50 copies/mL in a substantial proportion of patients (70% and 97% by intent-to-treat and on-treatment analyses), and improved immunological status of patients through week 204 (the mean increase from baseline in CD4+ cell count was 440 cells/µL), regardless of patient’s baseline immune status.

The efficacy of lopinavir/ritonavir 400/100mg twice daily in combination with lamivudine and stavudine compared favourably with that of a nelfinavir (750mg three times daily)-based PI-triple (a PI plus two NRTIs) regimen in a large randomised, double-blind phase III study in 653 antiretroviral therapy-naive adults with HIV-1 infection. Lopinavir/ritonavir demonstrated significantly greater suppression of plasma HIV-1 RNA levels than nelfinavir, starting from week 20 (<400 copies/mL) and week 32 (<50 copies/mL) and persisting through weeks 48 and 60. Significantly more patients receiving lopinavir/ritonavir-based triple therapy maintained viral response at both timepoints than recipients of the nelfinavir-based regimen. Both drugs had similar overall effects on patients’ immune systems; however, in patients with a very poor immune responsiveness at baseline (CD4+ cell count <50 cells/µL), lopinavir/ritonavir induced a significantly greater increase in the mean CD4+ cell count compared with nelfinavir, after 60 weeks of treatment. Lopinavir/ritonavir-based therapy was equally as effective in female as in male patients with HIV-1 infection, with or without hepatitis B and/or C virus (HBV/HCV) co-infection.

In 70 patients experiencing virological failure with treatment regimens comprising a single PI, alone or combined with one or more NRTI, substitution of their prior PI with lopinavir/ritonavir (400/100mg or 400/200mg twice daily) produced rapid (within the first 2 weeks of treatment) viral suppression (viral load <400 copies/mL or ≥1 log_{10} copies/mL reduction from baseline) in 80% of patients and rapid improvement in CD4+ cell count (increase was significant from week 8). These results were maintained at 48 weeks and for the duration of the study in patients who continued lopinavir/ritonavir-based salvage therapy, with no statistically significant differences recorded between the two lopinavir/ritonavir dosage combinations. At week 144, plasma HIV-1 RNA levels were suppressed below 400 copies/mL in at least half and below 50 copies/mL in almost half (49%) of the patients. All patients also received nevirapine and had their baseline
NRTI regimen changed to include at least one NRTI they had not received previously.

A smaller randomised, nonblind phase II trial in multiple PI-experienced but non-nucleoside reverse transcriptase inhibitor (NNRTI)-naive HIV-infected adults (n = 57) found two lopinavir/ritonavir dosage combinations (400/100mg vs 533/133mg twice daily) to have similar efficacy at 24 weeks in an antiretroviral regimen containing efavirenz 600mg once daily and NRTIs of the investigators’ choice. In the noncomparative extension of the study, treatment with the lopinavir/ritonavir 533/133mg twice-daily regimen maintained a high level of viral load suppression and continued to improve the CD4+ cell count, throughout week 72. Baseline in vitro phenotypic and genotypic susceptibility to lopinavir of viral isolates had an important influence on virological response throughout the course of study (see Overview of Pharmacodynamic Properties summary).

The efficacy of lopinavir/ritonavir coformulation has also been evaluated in two large (>11 000 participants in 35 countries worldwide) prospective, nonblind, noncomparative ‘salvage’ programmes (the Expanded Access Program [EAP] and the ATU programme [Autorisation Temporaire d’Utilisation] in HIV-1-infected adults who had failed to respond to and/or were intolerant to combinations of other available antiretroviral agents. Participants in both studies had significant prior exposure to both PIs and NNRTIs, and a large proportion had advanced disease on enrolment. In both studies patients received lopinavir/ritonavir 400/100mg twice daily with the dosage increase to 533/133mg if concomitant treatment included nevirapine or efavirenz. After the first 24 weeks of treatment with lopinavir/ritonavir-based salvage regimens in the EAP, overall >50% of patients achieved a viral load of ≤500 copies/mL, with ≈75% of patients attaining at least 1 log_{10} copies/mL reduction from baseline. In the ATU programme, a similar percentage (≈72%) of patients achieved viral response (defined as plasma HIV-1 RNA level <400 copies/mL or ≥1 log_{10} copies/mL decrease from baseline). An association was observed between the baseline lopinavir mutation score and the virological response to lopinavir/ritonavir-based treatment (see Overview of Pharmacodynamic Properties summary).

Data in children are limited to a nonblind, phase I/II study in antiretroviral therapy-naive (n = 44) and -experienced (n = 56) children (aged between 3 months and 12 years). All patients received regimens based on lopinavir/ritonavir 300/75 mg/m^2 twice daily (increased from 230/57.5mg twice daily after 3 weeks). After 72 weeks, lopinavir/ritonavir-based regimens adequately suppressed plasma HIV-1 RNA levels in most patients in both groups, although overall responses tended to be lower in experienced patients. Immune status of patients in each group continually improved throughout the study.

Coformulated lopinavir/ritonavir appeared to be well tolerated in both antiretroviral therapy-naive and -experienced children, in comparative and noncomparative clinical trials, which was reflected by the low rates of discontinuation of therapy (i.e. 4–7% through 60–204 weeks of therapy across the four comparative phase II/III trials in adults and 1% through 72 weeks of therapy in a single trial in children). This rate of discontinuation was unaffected by baseline HBV/HCV status in a phase III study in adults.

The most frequently reported adverse event in adults, of at least moderate severity, was diarrhea (12–31% incidence) in phase II/III clinical trials and in both antiretroviral therapy-naive and -experienced patients. Other less common complaints included other gastrointestinal disturbances (nausea, abdominal pain, vomiting), asthenia, headache and skin rash. The incidence of adverse events of at least moderate severity in children was low (11% overall); skin rash was the most common occurring in 2%, and allergic reactions, fever, viral infections, constipa-
tion, hepatomegaly, pancreatitis, vomiting, dry skin and taste perversion all occurred in 1% of patients. In the EAP, serious adverse events such as myocardial infarction, pancreatitis, lactic acidosis and hepatic failure were infrequent (<1%) during lopinavir/ritonavir therapy. Adverse events consistent with changes in body fat composition (including lipodystrophy, obesity and abdomen enlargement [2% each] and Cushingoid appearance, multiple lipomas and gynaecomastia [≤1% each]) were observed with equal frequency (7%) in lopinavir/ritonavir- or nelfinavir-treated ‘naive’ patients, through week 60 in the phase III study.

In the only phase III trial in adults, grade 3/4 laboratory abnormalities occurred with similar frequencies in lopinavir/ritonavir- and nelfinavir-treated ‘naive’ patients, except for the elevation in triglyceride levels, which occurred more frequently with lopinavir/ritonavir than with nelfinavir (11% vs 2%; p < 0.001). The incidence of grade 3/4 elevations in total cholesterol and triglycerides levels appears higher in PI-experienced than in antiretroviral therapy-naive patients receiving the coformulation, although evidence from direct comparison is still lacking. Biochemical abnormalities of grade 3/4 severity in children were infrequent (<6%).

Thus far, cost consequences of initiating antiretroviral therapy with lopinavir/ritonavir versus nelfinavir as the PI component in the triple regimen (in combination with lamivudine and stavudine) have been estimated in two pharmacoeconomic models. Both models analysed the results from a phase III study (see Therapeutic Efficacy summary) in 625 antiretroviral therapy-naive HIV-infected patients. Limited data from these analyses estimate a 60-week, 5-year and lifetime cost savings with coformulated lopinavir/ritonavir in comparison with nelfinavir based on higher treatment response rates achieved with the former drug. The estimated incremental cost effectiveness ratio with lopinavir/ritonavir was comparable to values calculated for generic antihypertensive drugs.

Coformulated lopinavir/ritonavir is approved for use in both antiretroviral therapy-naive and -experienced patients. It is available for oral administration in capsule and liquid formulations. The recommended dosage for adults, in the US, for the treatment of HIV-1 infection is 400/100mg (three capsules or 5mL oral solution) twice daily, and the coformulation should be administered with meals of moderate-to-high fat content in order to improve its oral bioavailability. The drug is indicated for use only in combination with other antiretroviral agents.

A number of clinically important drug interactions have been reported with lopinavir/ritonavir, necessitating dosage adjustments of lopinavir/ritonavir and/or the interacting drugs, and several drugs are contraindicated in patients receiving the coformulation (see Drug Interactions summary). Lopinavir/ritonavir is classified under pregnancy category C in the US. It should be administered with caution in patients with hepatic impairment and with haemophilia A and B.

1. Introduction

In the absence of a cure for HIV infection, the goals of antiretroviral therapy should be to improve patient survival and quality of life, reduce HIV-related morbidity, and restore and/or preserve immunological function through maximal and durable suppression of HIV replication. In order to achieve these goals, current treatment guidelines strongly recommend the use of triple-drug regimens comprising a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) with either a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI) as a first-line option for the initial treatment of early and advanced disease.

Lopinavir is a novel PI developed from, and structurally related to, ritonavir and with the same mechanism of action. The poor oral bioavailability of lopinavir coupled with its extensive and rapid metabolism in the liver, resulting in a short elimina-
tion half-life \( (t_{1/2}) \), precludes its use as a single PI agent in antiretroviral regimens. However, coadministration with subtherapeutic doses of ritonavir improves these pharmacokinetic properties of lopinavir allowing the drug to exert its highly potent antiretroviral activity.\(^{[3,4]}\)

The pharmacology and therapeutic use of coformulated lopinavir/ritonavir (Kaletra\(^{[6]}\)) has been briefly reviewed previously in *Drugs*.\(^{[5]}\) The current review provides an update on the pharmacokinetic efficacy and tolerability of coformulated lopinavir/ritonavir and its use in the management of HIV-1 infection. An overview of the pharmacodynamic and pharmacokinetic properties of lopinavir/ritonavir, including viral resistance and drug interactions, respectively, is also provided.

2. Overview of Pharmacodynamic Properties

Lopinavir/ritonavir is a coformulation of two structurally related PI antiretroviral agents. The pharmacodynamic properties of lopinavir, the therapeutically active antiviral component of the coformulation, have been briefly reviewed previously.\(^{[5]}\) This section provides a detailed overview of those properties.

2.1 Mechanism of Action

Lopinavir is a highly potent,\(^{[2]}\) peptidomimetic\(^{[6]}\) inhibitor of HIV-1 protease. A hydroxyethylene (instead of peptidic) bond within the molecule makes this drug a nonhydrolysable substrate for HIV-1 protease.\(^{[6,7]}\) This enzyme is a homodimeric aspartic protease involved in the post-translational processing of viral gag and gag-pol polyprotein products into functional core proteins and viral enzymes.\(^{[6,8]}\) This process, which occurs simultaneously with or immediately after the budding of the (immature) virion from the surface of an infected cell, is essential for the production of mature, infectious viral particles.\(^{[9]}\)

HIV PIs, including lopinavir, prevent cleavage of gag and gag-pol protein precursors in acutely and chronically infected cells, arresting maturation and thereby blocking the infectivity of nascent virions.\(^{[10,11]}\) The main antiviral action of HIV PIs is, thus, to prevent subsequent infection of susceptible cells; they have no effect on cells already harbouring integrated proviral DNA.

2.2 Antiretroviral Activity

2.2.1 In Vitro

Lopinavir has high specificity for HIV-1 protease, which it inhibits in vitro in both T-helper lymphocytes and cells of monocyte-macrophage lineage (two major cellular reservoirs for HIV-1 in infected individuals).\(^{[2]}\) It has greatly improved \((=10\text{-fold})\) in vitro antiretroviral activity and significantly higher binding affinity for both wild-type \((=8\text{-fold})\) and mutant \((=25\text{-}140\text{-fold})\) HIV-1 proteases compared with ritonavir.\(^{[2]}\)

Lopinavir 0.5 nmol/L inhibited 93% of wild-type HIV-1 protease activity in vitro and demonstrated \(\geq 10^5\text{-fold}\) higher specificity for this retroviral enzyme than for the mammalian aspartic proteases renin and cathepsin D and E.\(^{[2]}\) Its in vitro activity against both wild-type and V82-mutant HIV-1 proteases in MT4 cells was \(\approx 10\text{-fold}\) greater than that of ritonavir; the mean 50% effective concentrations \((\text{EC}_{50})\) of lopinavir and ritonavir against wild-type HIV-1 were 102 and 1 044 nmol/L, respectively, in a medium containing 50% human serum.\(^{[2]}\) Lopinavir was also active against primary HIV-1 isolates cultured in peripheral blood mononuclear cells, with an EC\(_{50}\) of 6.5 nmol/L in the absence of 50% human serum.\(^{[2]}\)

Both lopinavir and ritonavir exhibit high plasma protein binding that can attenuate their therapeutic efficacy (section 3.2). However, the in vitro anti-HIV-1 activity of lopinavir is \(\approx 4\text{-fold}\) less affected by plasma protein binding than is the activity of ritonavir.\(^{[12]}\) EC\(_{50}\) values for ritonavir against HIV-1 in the presence of 50% human serum were 20- to 30-fold higher than those observed in the absence of serum; in contrast, EC\(_{50}\) values for lopinavir increased by only 5- to 8-fold.\(^{[13]}\)

2.2.2 In Vivo

The in vivo activity of lopinavir is attenuated by a high first-pass hepatic metabolism (section 3.3). Coadministration of low-dose ritonavir with lopinavir inhibits metabolic inactivation of lopinavir and acts only as its pharmacokinetic enhancer. Combining lopinavir with low-dose ritonavir produces thera-

---

1 Use of tradenames is for product identification purposes only and does not imply endorsement.
peutic lopinavir concentrations exceeding those needed to inhibit HIV-1 activity in vivo.[2-4]

After a single 400mg oral dose in healthy volunteers, the peak lopinavir plasma concentrations (C_max) only briefly exceeded 0.1 mg/L (EC50 of lopinavir against wild-type HIV-1 in vitro).[2] However, coadministration of a single 50mg dose of ritonavir increased the lopinavir C_max to 5.5 mg/L and produced a 77-fold increase in 24-hour area under the plasma concentration-time curve (AUC).[2]

Mean steady-state trough lopinavir plasma concentrations (C_rough) with lopinavir/ritonavir 400/100mg twice-daily were 53- to 103-fold higher than the protein binding-adjusted EC50 of lopinavir against wild-type HIV-1 (0.07 mg/L) in antiretroviral therapy-naive HIV-1-infected patients (n = 45),[3] and exceeded the EC50 for all viral isolates phenotypically tested at baseline in single PI-experienced patients (n = 7).[4] The steady-state C_max of ritonavir in these trials (section 3.1) was <7% of that achieved with administration of therapeutic dosage of ritonavir in a single-PI regimen (i.e. 600mg twice daily)[5] and is below the EC50 against wild-type HIV-1 for this drug. Therefore, the antiretroviral activity of coformulated lopinavir/ritonavir 400/100mg twice daily is derived solely from lopinavir plasma concentrations.[15]

2.3 Resistance

There appears to be a lack of resistance development to lopinavir when coformulated with ritonavir in previously untreated patients (section 2.3.1). Thus far, cross-resistance to coformulated lopinavir/ritonavir has been observed to develop in 12% of HIV-1 strains in NNRTI-naive patients in whom prior treatment with multiple PIs had failed.[6] Not surprisingly, lopinavir/ritonavir has shown good therapeutic efficacy in 'salvage' antiretroviral regimens (section 5.1.2) owing to its apparently high barrier to development of resistance.

2.3.1 In Antiretroviral Therapy-Naive Patients

Thus far, no mutations associated with PI resistance have been detected in viral isolates from antiretroviral therapy-naive adult patients receiving lopinavir/ritonavir 400/100mg twice daily. Six (of 100)[6] and 51 (of 326)[10] patients with sustained viral load rebound (plasma HIV-1 RNA level >400 copies/mL), for whom genotype and phenotype data were available, were analysed up to weeks 20[17] and 96,[18] respectively (section 5.1.1 and table V). No mutations indicating PI resistance were found in the isolates from these patients.[17,18] In contrast, viral isolates from 50% (3 of 6)[17] and 37% (19 of 51)[18] of these patients demonstrated resistance to lamivudine.

2.3.2 In Protease Inhibitor (PI)- Experienced, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Naive Patients

In 57 multiple PI-experienced but NNRTI-naive HIV-infected patients (section 5.1.2), viral response to lopinavir/ritonavir-based antiretroviral regimens was influenced by baseline phenotype and genotype of viral isolates.[5,9,12] In vitro phenotypic susceptibility to lopinavir of the HIV-1 isolates obtained from study participants at baseline was 0.5-96 (median 16.2) times higher than the value of IC50 for wild-type HIV-1.[22] In 24 of 56 (43%) evaluable patients, the baseline viral isolates had ≥10-fold higher IC50 for lopinavir relative to wild-type virus.[20,21] Antiretroviral response rates at week 72 were highest among patients with baseline viral isolates displaying <10-fold reduction of in vitro susceptibility towards lopinavir compared with wild-type HIV-1 (93% and 89% response rate at <400 and <50 copies/mL) and, similarly, in patients with baseline viral isolates containing five or less protease mutations that were associated with reduced in vitro susceptibility to lopinavir (91% and 87% response rates at <400 and <50 copies/mL).[20,21] The response rates were lowest in patients with >40-fold reduced susceptibility to lopinavir and eight or more associated protease mutations at baseline (25% and 33% of patients had viral loads <400 and <50 copies/mL, respectively, for both parameters observed).[20,21] A statistically significant association was found between virological response to lopinavir/ritonavir-based treatment (at ≤400 and ≤50 copies/mL) and baseline phenotypic (p ≤ 0.001) and genotypic (p ≤ 0.022) susceptibility to lopinavir of HIV-1 isolates.[21]

2.3.3 In PI- and NNRTI- Experienced Patients

Similarly, interim results from 78 PI- and NNRTI-experienced patients from the Spanish Expanded Access Program (EAP; also referred to as the Early Access Program)[23] and from a subgroup of 179 PI- and NNRTI-experienced patients with baseline HIV-1 protease sequence analysis from the ATU programme (Autorisation Temporaire d’Utilisation)[24] [section 5.1.2] found strong negative corre-
lation between the number of PI mutations present at baseline and the viral response rates achieved at 6 months with lopinavir/ritonavir-based antiretroviral regimens. Patients harbouring HIV-1 RNA with five or less PI mutations at baseline had better viral response than patients with more than five PI mutations (83% and 88% vs 48% and 51%; p < 0.001)\(^{12,13}\). Substitutions at codons 71 and 82 were the only mutations in the viral genome independently associated with a lower viral response to lopinavir/ritonavir in the Spanish EAP (p = 0.04 and 0.053, respectively)\(^{23}\), whereas in an overall analysis of 793 patients from the ATU programme such mutations were found at positions 10, 20, 36, 46, 54 and 82 (all p < 0.01 vs baseline genotype)\(^{15}\).

The results from these lopinavir/ritonavir trials in PI-experienced patients indicate that resistance to lopinavir is proportional to the number of PI mutations and that five PI mutations could represent the point at which clinically relevant reduction in lopinavir sensitivity begins to occur\(^{20,23,24}\).

### 2.3.4 In Children with HIV-1 Infection

Data regarding resistance to coformulated lopinavir/ritonavir in children are limited. Among 20 PI- and NNRTI-experienced HIV-1-infected children with available baseline phenotypes in a phase I/II study (section 5.2 and table VIII), 33% (1 of 3 patients) with >10-fold and 59% (10 of 17 patients) with <10-fold reduced baseline susceptibility to lopinavir had <400 copies/mL of HIV-1 RNA in plasma at week 72\(^{26}\).

### 3. Overview of Pharmacokinetic Properties

The pharmacokinetic properties of lopinavir coadministered with ritonavir have been evaluated in single- (400/50mg\(^{[2]}\) and 400/100mg\(^{[14]}\)) and multiple-dose\(^{[4,27,30]}\) studies in healthy adult volunteers (n = 75\(^{[27]}\), 54\(^{[14]}\) and 14\(^{[23]}\)) and in HIV-1-infected adults who were antiretroviral therapy-naive (n = 46\(^{[14]}\) and 38\(^{[28,30]}\)) or had prior experience with a single PI drug (n = 12).\(^{[14]}\) Except in one pilot study,\(^{[2]}\) lopinavir and ritonavir were administered coformulated in capsules\(^{[4,27,30]}\) or in oral solution.\(^{[14]}\) In multiple-dose studies, the coformulation was administered in once-\(^{[27,30]}\) or twice-daily\(^{[4,27,30]}\) regimens, with food\(^{[28,30]}\) or without regard to food intake.\(^{[4,27]}\) Antiretroviral therapy-naive and single PI-experienced patients also received standard doses of stavudine and lamivudine, and nevirapine and two NRTIs, respectively, in addition to lopinavir/ritonavir in two multiple-dose studies.\(^{[4]}\) Some data are extracted from the manufacturer’s prescribing information.\(^{[15]}\)

The previous review in Drugs\(^{[5]}\) gave an insight into the pharmacokinetic profile of lopinavir. This section provides an overview of the pharmacokinetic properties of lopinavir when coformulated with low-dose ritonavir.

#### 3.1 Absorption

The absolute bioavailability of lopinavir coformulated with ritonavir in humans has not yet been established.\(^{[15]}\) The calculated oral bioavailability of lopinavir (without coadministration of ritonavir) in rats is low (25%).\(^{[2]}\)

Combining lopinavir with low-dose ritonavir produces therapeutic lopinavir concentrations exceeding those needed to inhibit HIV-1 activity in vivo (section 2.2.2). After a single oral 400mg dose of lopinavir in healthy volunteers (n = 14), plasma concentrations only briefly exceeded the EC\(_{50}\) (0.1 mg/L) and declined to >10-fold lower values by 8 hours. Coadministration of a single 50mg dose of ritonavir, however, produced sustained elevation of lopinavir C\(_{\text{max}}\) above EC\(_{50}\) reaching 5.5 mg/L. Likewise, the AUC of lopinavir was increased 77-fold from 0–24 hours by coadministration of low-dose ritonavir.\(^{[13]}\)

Multiple-dosage absorption pharmacokinetics of lopinavir/ritonavir 400/100mg twice daily (n = 19) and 800/200mg once daily (n = 17) in antiretroviral therapy-naive patients are summarised in table I.\(^{[28,30]}\) The C\(_{\text{trough}}\) and inhibitory quotient values (IQ; defined as the ratio between the C\(_{\text{trough}}\) and the protein-binding-adjusted EC\(_{50}\)\(^{[11]}\)) or the concentration required to inhibit 50% of viral activity [IC\(_{50}\)]\(^{[12]}\) for wild-type HIV-1 from weeks 3 to 48 were lower and more variable in the once-daily compared with the twice-daily regimen (p < 0.01).\(^{[28,30]}\) The IQ for the twice-daily regimen ranged from 36 to 174 (median 84)\(^{[28,29]}\).

In another study, the multiple-dosage absorption pharmacokinetics of both lopinavir and ritonavir in the 400/100mg twice-daily regimen were stable over a 24-week evaluation period; values for the C\(_{\text{max}}\), C\(_{\text{trough}}\) and AUC\(_{12}\) for either drug were similar within the ‘naive’ (n = 18) and the ‘experienced’ (n = 7) patient population over weeks 3–24.\(^{[14]}\) There was a strong positive linear correlation between the
Table I. Absorption pharmacokinetics of oral lopinavir/ritonavir coformulated as a capsule in adults with HIV-1 infection. Preliminary 48-week results from an ongoing, randomised, pilot study in antiretroviral therapy-naive patients receiving lopinavir/ritonavir 400/100mg bid (n = 19) or 800/200mg od (n = 17) with food [28,29]

<table>
<thead>
<tr>
<th>Lopinavir/ritonavir</th>
<th>Lopinavir</th>
<th>Ritonavir</th>
</tr>
</thead>
<tbody>
<tr>
<td>dosage</td>
<td>C&lt;sub&gt;max&lt;/sub&gt; (mg/L)</td>
<td>C&lt;sub&gt;trough&lt;/sub&gt; (mg/L)</td>
</tr>
<tr>
<td>400/100mg bid</td>
<td>9.8</td>
<td>7.1</td>
</tr>
<tr>
<td>800/200mg od</td>
<td>10.9</td>
<td>3.6*</td>
</tr>
</tbody>
</table>

<sup>a</sup> Patients were also receiving lamivudine 150mg and stavudine 30 or 40mg twice daily.

<sup>b</sup> Estimated by investigators as 2 x AUC<sub>12</sub>.

AUC<sub>12(24)</sub> = area under the drug plasma concentration-time curve during 12 (24)-hour administration period; bid = twice daily; C<sub>max</sub> = peak plasma drug concentration; C<sub>trough</sub> = trough plasma drug concentration at steady-state; od = once daily; t<sub>max</sub> = time to reach C<sub>max</sub> following drug administration; * p < 0.05 between treatment regimens.

C<sub>trough</sub>, C<sub>max</sub> and AUC of lopinavir and ritonavir for the 400/100mg regimen of the coformulated drug (r = 0.74, 0.64 and 0.61, for the respective parameters; all p < 0.001).<sup>[4]</sup>

3.1.1 Effects of Food on Oral Absorption

The bioavailability of lopinavir administered in either the capsule or the liquid lopinavir/ritonavir formulation can be increased substantially with concurrent ingestion of food with moderate-to-high fat content. Therefore, it is recommended that lopinavir/ritonavir be administered with moderate-to-high-fat content meals.<sup>[14,15]</sup> The apparent effect is greater for the liquid than for the soft elastic capsule formulation (figure 1).

3.2 Distribution

At steady state, lopinavir is highly bound to both albumin and α1-acid glycoprotein, with higher affinity for the latter.<sup>[15]</sup> In previous studies in both healthy volunteers and HIV-1-infected adults, plasma protein binding of lopinavir ranged from 98.2% to 99.2% and did not appear to be concentration dependent within the therapeutic range.<sup>[4,27]</sup> However, in a recent study in 15 HIV-infected patients the percentage of unbound lopinavir was proportional to the total drug plasma concentration (p = 0.027, r = 0.57, linear regression analysis) and was ~60% higher 2 hours, compared with 12 hours, after lopinavir/ritonavir administration.<sup>[33]</sup>

High plasma protein binding is thought to be a likely explanation for undetectable lopinavir levels in the cerebrospinal fluid (CSF) of all (n = 12) adult patients with HIV-1 infection receiving lopinavir/ritonavir 400/100mg twice daily in combination with two NRTIs after 6 months of treatment.<sup>[33]</sup>

Direct measurements of drug concentrations taken on two separate occasions in plasma and cervicovaginal secretions of HIV-1-infected women (n = 5<sup>[35]</sup> and 17<sup>[36]</sup>) receiving lopinavir/ritonavir (dosage not specified) have shown poor penetration of lopinavir and ritonavir into the female genital tract (<10%<sup>[35]</sup> and <4%<sup>[36]</sup> of their respective plasma concentrations 12 hours after drug administration). In comparison, cervicovaginal concentrations of indinavir, nevirapine and delavirdine were <0.5% and <4% of their respective plasma concentrations at the same timepoint.<sup>[35,36]</sup>

Similar observations were recently made about penetration of lopinavir into the male genital tract. Penetration of lopinavir into the seminal plasma was very limited in 14 men with HIV-1 infection receiving a lopinavir-containing regimen (dosage not specified) for 4–41 weeks (a median of 16 weeks). All but one patient had seminal plasma concentrations of <0.5 mg/L (estimated from a graph) and none had concentrations >5.0 mg/L (the desired therapeutic concentration).<sup>[37,38]</sup> Another study reported a median lopinavir concentration ratio in semen and plasma of 7%, but with a large inter-individual variability in the level of lopinavir penetration into semen (0.08–2.35 mg/L; median 0.17 mg/L) in seven men with HIV-1 infection receiving lopinavir/ritonavir 400/100mg twice daily for 6 months in combination with two NRTIs.<sup>[34]</sup>

3.3 Metabolism

Studies in human hepatic microsome preparations indicate that both lopinavir and ritonavir undergo extensive and rapid first-pass oxidative metabolism in the liver.<sup>[39,40]</sup> Enzymatic inactivation of lopinavir in the liver is mediated by the cytochrome P450 (CYP) 3A4 isoenzyme, while that of ritonavir is carried out by both CYP3A and CYP2D6.<sup>[39,40]</sup> Ritonavir is also a highly potent inhibitor of
CYP3A-mediated metabolic reactions. Thus, co-administration of ritonavir, even in the subtherapeutic dosage range, can significantly enhance the pharmacokinetic properties of lopinavir (section 3.1). In contrast, the concentration of ritonavir required to inhibit the metabolism of saquinavir in human liver microsomes is 3.4-fold higher than that needed to inhibit the metabolism of lopinavir.\(^{2,42}\)

3.4 Elimination

The mean \( t_1/2 \) and apparent oral clearance of lopinavir were 4.1–5.8 hours and 6.0–7.1 L/h, respectively, during 24-week trials with lopinavir/ritonavir 400/100mg twice-daily administration in antiretroviral therapy-naive or -experienced patients.\(^{4}\) After a single administration of the same dose of \(^{14}\)C-labelled lopinavir/ritonavir, \( \approx 10.4\% \) and 82.6\% of \(^{14}\)C-lopinavir was retrieved in the urine and faeces after 8 days. Approximately 2.2\% and 19.8\% of lopinavir was recovered unchanged in the urine and faeces. After administration of multiple doses of lopinavir/ritonavir, \( <3\% \) of the lopinavir dose is excreted unchanged in the urine.\(^{15}\)

3.5 In Special Patient Populations

Thus far, pharmacokinetics of lopinavir have not been studied in elderly patients, nor in patients with hepatic insufficiency.\(^{15}\) Sex- and race-related differences in pharmacokinetic properties of lopinavir have not been observed in adult patients.\(^{15}\) A single case report in an HIV-1-infected patient with renal insufficiency indicated that haemodialysis had no influence on the pharmacokinetics of lopinavir.\(^{43}\)

3.5.1 In Children

The pharmacokinetics of lopinavir/ritonavir liquid formulation have been investigated in 53 children (aged between 6 months and 12 years) with HIV-1 infection (see section 5.2 for study details). During a 3-week trial, the 230/57.5 mg/m\(^2\) twice-daily lopinavir/ritonavir regimen without nevirapine and the 300/75 mg/m\(^2\) twice-daily regimen with nevirapine produced similar lopinavir plasma concentrations to those achieved in HIV-1-infected adults receiving the lopinavir/ritonavir 400/100mg twice-daily regimen.\(^{15}\)

At steady state, lopinavir AUC, \( C_{\text{max}} \) and \( C_{\text{trough}} \) for these two paediatric regimens were 72.6 and 85.8 mg \( \cdot \) h/L, 8.2 and 10.0 mg/L, and 3.4 and 3.6 mg/L, respectively.\(^{15}\)

4. Drug Interactions

Lopinavir and ritonavir are both metabolised through CYP pathways (section 3.3) and therefore have the potential for interactions with a wide variety of drugs.\(^{44}\) In addition to being a substrate for hepatic CYP3A4 (section 4.2.3), coformulated lopinavir/ritonavir acts as both a strong inducer and inhibitor of this enzyme (section 4.1 and 4.2.2) and as an inhibitor of CYP2D6 isoenzyme. Ritonavir also increases the biotransformation of some drugs metabolised by glucuronidation (section 4.2.2).

Pharmacokinetic and pharmacodynamic interactions between lopinavir/ritonavir and other drugs have been investigated in trials in small numbers of
HIV-1-infected patients[45] or healthy volunteers.[15,46-48] Some information is available only from the manufacturer’s prescribing information.[15] The majority of these studies evaluated only two-drug regimens and their results may not necessarily be applicable to the multidrug regimens often used in clinical practice. This is especially true for regimens comprising three or more drugs with opposing effects on CYP3A4-mediated metabolism, where multidrug interactions may be difficult to predict, thus warranting even closer monitoring for adverse events and/or treatment failure.

4.1 Drugs Not to Be Coadministered with Lopinavir/Ritonavir

According to the manufacturer’s prescribing information, coadministration of lopinavir/ritonavir is contraindicated with certain drugs that are highly dependent on CYP3A or CYP2D6 for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (table II).[15] In contrast, a recent study in healthy volunteers (n = 15) indicates that the activity of CYP2D6 is not affected by clinically relevant concentrations of lopinavir/ritonavir.[48] Lopinavir/ritonavir may elevate plasma concentrations of the lipid-lowering drugs simvastatin or lovastatin, potentially leading to serious adverse reactions (e.g. myopathy including rhabdomyolysis). Hence, their coadministration with lopinavir/ritonavir is not recommended.[15] As an alternative, atorvastatin (section 4.2.2) or pravastatin may be used.

Table II. Drugs contraindicated for use with lopinavir/ritonavir[15]

<table>
<thead>
<tr>
<th>Drug class (drug name)</th>
<th>Potential clinical effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiarrhythmics (flecainide, propafenone)</td>
<td>Cardiac arrhythmias</td>
</tr>
<tr>
<td>Antihistamines (astemizole, terfenadine)</td>
<td>Cardiac arrhythmias</td>
</tr>
<tr>
<td>GI motility agent (cisapride)</td>
<td>Cardiac arrhythmias</td>
</tr>
<tr>
<td>Neuroleptic (pimozide)</td>
<td>Cardiac arrhythmias</td>
</tr>
<tr>
<td>Ergot derivatives (ergonovine, methylergonovine, ergotamine, dihydriodolergotamine)</td>
<td>Acute ergot toxicity (i.e. peripheral vasospasm and ischaemia of the extremities and other tissues)</td>
</tr>
<tr>
<td>Sedative/hypnotics (midazolam, triazolam)</td>
<td>Prolonged or increased sedation, respiratory depression</td>
</tr>
</tbody>
</table>

a No longer available in the US.
GI = gastrointestinal.

Concomitant use of lopinavir/ritonavir with the antimycobacterial agent rifampicin (rifampin), at standard dosages, or the herbal product St. John’s wort (Hypericum perforatum) is also not recommended as both drugs may substantially reduce lopinavir plasma concentrations (through induction of lopinavir/ritonavir metabolism), leading to loss of virological response and possible development of resistance to lopinavir/ritonavir or other PI agents.[15,46,47] However, a recent study in healthy adult volunteers (n = 32) indicated that increasing the dosage of lopinavir/ritonavir (i.e. to 400/400mg and possibly 800/200mg, twice daily) in conjunction with therapeutic drug monitoring may allow for concurrent use of rifampicin 600mg once daily in the treatment of tuberculosis in patients with HIV-1 infection.[49] These results are encouraging, although further studies addressing drug tolerability at these dosages will be necessary.

The liquid formulation of lopinavir/ritonavir contains 42.4% ethanol (v/v)[15] and should not be coadministered with drugs, such as disulfiram or metronidazole, capable of producing disulfiram-like reactions (i.e. nausea, vomiting, flushing, tachypnea, tachycardia). The capsule formulation does not contain alcohol.[15]

4.2 Concomitant Drug Administration

4.2.1 Interactions Between Lopinavir/Ritonavir and Other Antiretroviral Drugs

Successful antiretroviral therapy requires a combination of at least two and preferably three or more drugs from different classes (i.e. with different mechanisms of action).[50,51] Coadministration of lopinavir/ritonavir with other antiretroviral drugs may result in clinically relevant pharmacokinetic drug interactions. Table III summarises the effects on absorption pharmacokinetics (Cmax, Ctrough, and AUC) of coadministered antiretroviral drugs on lopinavir and/or vice versa in adults (either patients with HIV infection or healthy volunteers).

Interactions with PIs
All PIs are extensively metabolised by CYP enzymes (particularly the CYP3A4 isoenzyme) and drug interactions within this drug class (see table III for details) occur primarily as a result of induction or inhibition of this enzyme.[61]

As the Cmax, Ctrough and AUC of lopinavir are decreased (table III) during coadministration with...
Table III. Summary of absorption pharmacokinetic drug interactions between lopinavir/ritonavir (LPV/r) 400/100mg twice daily (bid) and other antiretroviral drugs in adults

<table>
<thead>
<tr>
<th>Coadministered drug regimen (mg)</th>
<th>No. of participants</th>
<th>Effect of coadministered drug on LPV pharmacokinetics (% change)</th>
<th>Effect of LPV/r on coadministered drug pharmacokinetics (% change)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Cmax</td>
<td>Ctrough</td>
</tr>
<tr>
<td>In combination with other protease inhibitors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amprenavir 750 bid [10][43]</td>
<td>12 (vol)</td>
<td>↓27*</td>
<td>↓49*</td>
</tr>
<tr>
<td>Indinavir 600 bid [10][28]</td>
<td>13 (vol)</td>
<td>↑18b</td>
<td>↓6b</td>
</tr>
<tr>
<td>Saquinavir 800 bid [10][25]</td>
<td>14 (vol)</td>
<td>↑13b</td>
<td>0b</td>
</tr>
<tr>
<td>Saquinavir 1200 bid [10][23]</td>
<td>10 (vol)</td>
<td>↑5b</td>
<td>↓8b</td>
</tr>
<tr>
<td>In combination with non-nucleoside reverse transcriptase inhibitors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efavirenz 600 qhs [9][26]</td>
<td>11 (vol)</td>
<td>↓3</td>
<td>↓28</td>
</tr>
<tr>
<td>Efavirenz 600 qhs [14][35]</td>
<td>24 (pts)</td>
<td>↓15a</td>
<td>↓31a</td>
</tr>
<tr>
<td>Efavirenz 600 od [35][25,50]</td>
<td>57 (pts)</td>
<td>↓33b</td>
<td>↓25b</td>
</tr>
<tr>
<td>Nevirapine 200 od [14] followed by nevirapine 200 bid [6][27]</td>
<td>5 (vol)</td>
<td>↓5</td>
<td>↑2</td>
</tr>
<tr>
<td>Nevirapine 200 bid[28]</td>
<td>22 (pts)</td>
<td>↓19a</td>
<td>↓46m</td>
</tr>
<tr>
<td>In combination with a nucleotide reverse transcriptase inhibitor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tenofovir disoproxil fumarate 300 od [14][25,62]</td>
<td>24 (vol)</td>
<td>↓15f</td>
<td>↓10</td>
</tr>
</tbody>
</table>

a Compared with amprenavir values in 11 vol receiving amprenavir 1200mg bid for 15d.
b Compared with historical data in 19 pts receiving LPV/r 400/100mg bid for 21d.[34]
c Compared with indinavir values in 13 vol receiving indinavir 800mg tid for 5d.
d Compared with saquinavir values in 14 vol receiving saquinavir 1200mg tid for 5d.
e Compared with historical controls receiving LPV/r 400/100mg bid alone.
f Pts were also receiving nucleoside reverse transcriptase inhibitors. Steady-state pharmacokinetic values are reported.

AUC = area under the drug plasma concentration-time curve; Cmax = peak plasma drug concentration; Ctrough = trough plasma drug concentration; od = once daily; pts = patients with HIV-1 infection; qhs = once daily at bedtime; tid = three times daily; vol = healthy volunteers; ↓ indicates decrease; ↑ indicates increase; * p < 0.05 vs comparator regimen; † statistical significance established at 90% CI.

amprénavir, the dosage of lopinavir/ritonavir should be increased typically by 33% (i.e. to 533/133mg twice daily in adults), particularly in patients with extensive PI experience or with reduced viral susceptibility to lopinavir.[23] In contrast, from comparisons with historical data,[54] the pharmacokinetics of lopinavir (table III) and ritonavir appear to be only minimally affected by coadministration of saquinavir and indinavir requiring no dosage adjustment of lopinavir/ritonavir.

Lopinavir/ritonavir 400/100mg twice daily significantly enhanced absorption pharmacokinetics of saquinavir administered in the 800mg twice-daily regimen (table III), resulting in ≈19-fold increase in the median IQ of saquinavir (compared with results with saquinavir 1200mg three-times-daily regimen).[53] An increase in the saquinavir dosage from 800 to 1200mg twice daily was, however, not associated with an expected increase in saquinavir absorption pharmacokinetics, suggesting a plateau effect with the lower-dose regimen.

Coadministration of lopinavir/ritonavir 400/100mg and indinavir 600mg twice daily resulted in a statistically significant decrease in the indinavir Cmax and an increase in Ctrough (compared with results with indinavir 800mg three times daily) [table III and increased the median IQ of indinavir from 4.3 to 11).[53] Thus, the in vitro antiretroviral activity of indinavir, like that of saquinavir, is increased allowing for reduction in dosage and frequency of administration when indinavir, or saquinavir, is coadministered with lopinavir/ritonavir (table III). Appropriate dosages of indinavir, saquinavir and amprénavir when administered in combination with lopinavir/ritonavir have not yet been established (see section 8).

Interactions with NNRTIs
Pharmacokinetic interactions between lopinavir/ritonavir and nevirapine or efavirenz are related to
their common metabolic pathways; both NNRTIs are metabolised by CYP3A (like lopinavir and ritonavir) and to a lesser extent by CYP2D6 (like ritonavir), and they both act as potent CYP3A enzyme inducers (like ritonavir).\textsuperscript{[57,58,62]} Despite some conflicting results with nevirapine regarding a lack of interaction in healthy volunteers (table III), coadministration of either of these two NNRTIs with lopinavir/ritonavir generally results in statistically significantly decreased lopinavir plasma concentrations (table III). Consequently, a 33\% increase in lopinavir/ritonavir dosage is recommended when the coformulation is coadministered with either nevirapine or efavirenz to achieve therapeutic lopinavir plasma concentrations,\textsuperscript{[15,55,57,62]} although the clinical relevance of pharmacokinetic interactions between nevirapine and lopinavir/ritonavir has not been definitely established.\textsuperscript{[58]}

Dosage adjustment of efavirenz or nevirapine is not required when coadministered with lopinavir/ritonavir, as the latter drug only marginally alters the $C_{\text{max}}$, $C_{\text{trough}}$ and AUC of these NNRTIs, as shown in healthy volunteers (table III).\textsuperscript{[55,57]}

Interactions with Nucleoside or Nucleotide Reverse Transcriptase Inhibitors

Lopinavir/ritonavir is also commonly prescribed in combination with NRTIs. However, pharmacokinetic drug interactions are unlikely as their metabolic pathways do not involve the CYP enzymes responsible for inactivation of lopinavir/ritonavir. Whether lopinavir/ritonavir interferes with intracellular phosphorylation of NRTIs, required for their activation against HIV-1,\textsuperscript{[63]} is unknown.\textsuperscript{[61]}

Administration of tenofovir disoproxil fumarate, a nucleotide reverse transcriptase inhibitor, with lopinavir/ritonavir in healthy volunteers did not result in clinically relevant alterations of pharmacokinetics of either drug (table III).\textsuperscript{[59,60]}

The oral bioavailability of both didanosine and lopinavir/ritonavir is significantly affected by concurrent food ingestion; the extent of their absorption is reduced (didanosine)\textsuperscript{[64]} or increased (lopinavir) \textsuperscript{[figure 1]}\textsuperscript{[14,15]} by \textapprox=50\% in the presence of food. Therefore, it is recommended that didanosine be administered 1 hour before or 2 hours after lopinavir/ritonavir has been taken with food.\textsuperscript{[15]}

### 4.2.2 Effect of Lopinavir/Ritonavir on Non-Antiretroviral Drugs

Both lopinavir and ritonavir inhibit CYP3A \textit{in vitro}\textsuperscript{[41]} and \textit{in vivo} and their combination is likely to increase plasma concentrations of other drugs metabolised through this pathway, thus increasing the risk of toxicity. The list of drugs potentially affected in this manner and the clinical recommendations for their concurrent use with lopinavir/ritonavir are presented in table IV.\textsuperscript{[15,46,47]}

In healthy volunteers, lopinavir/ritonavir 400/100mg twice daily significantly (statistical signifi-

### Table IV. Drugs whose plasma concentration can be potentially significantly increased when coadministered with lopinavir/ritonavir and clinical recommendations for their dosage adjustment\textsuperscript{[15,46,47,60]}

<table>
<thead>
<tr>
<th>Drug class (drug name)</th>
<th>Clinical recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiarrhythmics (amiodarone, bepridil, lidocaine [systemic], quinidine)</td>
<td>Therapeutic drug plasma concentration monitoring</td>
</tr>
<tr>
<td>Immunosuppressants (cyclosporin, tacrolimus, rapamycin)</td>
<td>Therapeutic drug plasma concentration monitoring</td>
</tr>
<tr>
<td>Anti-infective agent (clarithromycin)</td>
<td>Dosage adjustment in patients with renal failure</td>
</tr>
<tr>
<td>Antimycobacterial agent (rifabutin)\textsuperscript{a}</td>
<td>Use \leq25% of usual dosage; monitor closely for adverse events</td>
</tr>
<tr>
<td>Dihydropyridine calcium-channel blockers (e.g. felodipine, nicardipine, nifedipine)</td>
<td>Monitor closely for adverse events; adjust dosage accordingly</td>
</tr>
<tr>
<td>Erectile dysfunction agent (sildenafil)</td>
<td>Use with caution at 25mg every other day; monitor closely for adverse events</td>
</tr>
<tr>
<td>Lipid-lowering agent, HMG-CoA reductase inhibitor (atorvastatin)\textsuperscript{b}</td>
<td>Use lowest therapeutic dosage\textsuperscript{c} or consider pravastatin; monitor closely for adverse events</td>
</tr>
<tr>
<td>Antifungal agents (ketoconazole, itraconazole)</td>
<td>Dosages \geq200mg once daily not recommended\textsuperscript{d}</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Based on effects on the $C_{\text{max}}$ and AUC in a study in 12 healthy volunteers receiving lopinavir/ritonavir 400/100mg twice daily.\textsuperscript{[15,46,47]}

\textsuperscript{b} The usual dosage of rifabutin is 300mg once daily. Further dosage reduction may be necessary with long-term use.

\textsuperscript{c} Start with \leq10mg of atorvastatin daily.

\textsuperscript{d} Lopinavir/ritonavir induced a 3-fold increase in the AUC of ketoconazole as a 200mg single dose, although the change in the $C_{\text{max}}$ was not significant.\textsuperscript{[15,46,47]}

AUC = area under the drug plasma concentration-time curve; $C_{\text{max}}$ = peak plasma drug concentration.
cance established using 90% CI) reduced the $C_{\text{max}}$ and AUC of methadone and ethinyl estradiol (suggesting the need for an alternative or backup method of contraception for HIV-1-positive women receiving the coformulation).\cite{15,46,47} In HIV-1 infected patients receiving lopinavir/ritonavir with stable doses of methadone, the $C_{\text{max}}$ and AUC were similarly reduced;\cite{66} however, there was no requirement for methadone dosage adjustment and patients did not manifest opioid withdrawal symptoms.\cite{45,66} Finally, lopinavir/ritonavir may alter the plasma concentration of warfarin and therefore close monitoring of the international normalised ratio is recommended.\cite{15}

### 4.2.3 Effects of Non-Antiretroviral Drugs on Lopinavir/Ritonavir

Drugs that induce CYP3A isoenzymes may increase the clearance of lopinavir and lower its concentration in plasma, thus reducing its therapeutic efficacy. Hence, corticosteroids, particularly dexamethasone, which are potent inducers of CYP-mediated oxidative metabolism, should be used with caution in patients receiving lopinavir/ritonavir.\cite{15} Likewise, certain anticonvulsants (e.g. carbamazepine, phenytoin and barbiturates) may decrease lopinavir plasma concentrations and warrant appropriate dosage adjustment of the coformulation when administered concomitantly.\cite{15}

### 5. Therapeutic Efficacy

The therapeutic efficacy of lopinavir/ritonavir capsules and oral solution in combination with other antiretroviral agents has been evaluated in several clinical trials in patients with HIV infection.\cite{3,20,26,67,68} The majority of recent data are available only as abstracts or posters, although the 48-week results of three prospective, randomised, double-blind studies\cite{3,67,68} and a 6-month interim report from a ‘national’ EAP\cite{23} have been fully published.

Morbidity (e.g. incidence of opportunistic infections and malignancies) and mortality represent the primary clinical efficacy endpoints for antiretroviral therapy in patients infected with HIV-1. However, the clinical trials evaluating the lopinavir/ritonavir-based therapy in this patient population used two surrogate markers of disease progression to determine the efficacy of the coformulation: an immunological (i.e. CD4+ cell count) and a virological (i.e. plasma HIV-1 RNA level [viral load]) marker. Both markers are highly predictive of disease progression to AIDS and death\cite{69-73} and are used to guide the decisions to initiate or change the treatment of HIV-1 infection and to assess its effectiveness. Trials in HIV-infected patients used surrogate markers. The effects of lopinavir/ritonavir on HIV-1- and AIDS-related morbidity and/or mortality are yet to be established.

Lopinavir/ritonavir has been evaluated in combination with other antiretroviral agents both in HIV-positive patients who had not previously received antiretroviral treatment (i.e. antiretroviral therapy-naive patients)\cite{3,26,68} and in those who had received prior antiretroviral treatment (i.e. antiretroviral therapy-experienced patients).\cite{20,26,67,74-78} The lopinavir/ritonavir-based regimes have been evaluated both in comparative\cite{3,20,26,67,68} and noncomparative\cite{74-78} clinical trials and separately in adults\cite{3,20,26,67,68,74-78} and in children\cite{26} infected with HIV-1.

Results from clinical trials in this section are reported according to patients enrolled (intent-to-treat [ITT] analysis) and to evaluable patients who remained on study medication (on-treatment [OT] analysis) at the time of efficacy assessment. Virological responses (i.e. plasma HIV-1 RNA levels) are reported in both ITT and OT analyses, whereas immunological responses (i.e. CD4+ cell counts) correlate to OT analysis only.

All clinical trials evaluating the efficacy of lopinavir/ritonavir utilised two lower levels of quantitation (LLQs) for plasma HIV RNA levels: <400 copies/mL and <50 copies/mL; the latter LLQ represents a more reliable predictor of durable virological response to antiretroviral therapy.\cite{79}

#### 5.1 In Adults

Thus far, four ongoing, prospective, randomised, multicentre clinical trials have investigated the efficacy of lopinavir/ritonavir in combination with either NRTIs\cite{3,68} or NRTIs plus an NNRTI\cite{20,67} in HIV-infected adults. Three trials\cite{3,67,68} were double-blind (table V) and one\cite{20} was nonblind. Two clinical trials included only antiretroviral therapy-naive patients (table V).\cite{3,68} The other two trials included only NNRTI-naive patients with a history of treatment with a single (i.e. single PI-experienced patients)\cite{table V}\cite{67} or multiple (i.e. multiple PI-experienced patients) PI’s.\cite{20} The phase II trials compared the efficacy of various dose combinations of lopinavir coformulated with ritonavir. The only
Table V. Summary of randomised, double-blind, multicentre clinical trials of lopinavir/ritonavir (LPV/r) in adult patients (pts) with HIV infection. All treatment regimens were administered twice daily unless stated otherwise

<table>
<thead>
<tr>
<th>Reference</th>
<th>No. of pts (duration of treatment [w])</th>
<th>Treatment regimen (mg)</th>
<th>Plasma viral load (log_{10} copies/mL)</th>
<th>CD4+ count (cells/µL)</th>
<th>Pts with plasma viral load below LLQ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>baseline change at week 2</td>
<td>baseline change at study end</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&lt;400 copies/mL</td>
<td>=&lt;50 copies/mL</td>
<td></td>
</tr>
<tr>
<td><strong>Dose-comparison trial in antiretroviral therapy-naive patients</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Murphy et al.;[3] 16 (48) [group Ia]</td>
<td>LPV/r 200/100 +3TC +d4T b</td>
<td>4.88 ↓1.73c</td>
<td>471</td>
<td>&gt;205i</td>
<td>100/100</td>
</tr>
<tr>
<td>16 (48) [group Ia]</td>
<td>LPV/r 400/100 +3TC +d4T b</td>
<td>4.96 ↓1.73c</td>
<td>330</td>
<td>&gt;276d</td>
<td>81/93</td>
</tr>
<tr>
<td>35 (48) [group II]</td>
<td>LPV/r 400/100 +3TC +d4T b</td>
<td>4.78 ↓1.68e</td>
<td>343</td>
<td>&gt;226e</td>
<td>91/100</td>
</tr>
<tr>
<td>33 (48) [group II]</td>
<td>LPV/r 400/200 +3TC +d4T b</td>
<td>4.97 ↓1.68e</td>
<td>275</td>
<td>&gt;197d</td>
<td>80/80</td>
</tr>
<tr>
<td><strong>Comparison vs nelfinavir (NFV) in antiretroviral therapy-naive patients</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Walmsley et al.;[68] 326 (48)</td>
<td>LPV/r 400/100 +3TC +d4T b</td>
<td>4.89</td>
<td>260</td>
<td>&gt;207</td>
<td>75***/93***</td>
</tr>
<tr>
<td>Johnson et al.;[83]fg 326 (60)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ruane et al.[84]f 327 (48)</td>
<td>NFV 750 tid +3TC +d4T b</td>
<td>4.92</td>
<td>258</td>
<td>&gt;195</td>
<td>61/69</td>
</tr>
<tr>
<td>327 (60)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dose-comparison trial in single PI-experienced, NNRTI-naive patients</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benson et al.;[77] 36 (48)</td>
<td>LPV/r 400/100’ +NVPi +2 NRTIs j</td>
<td>4.1 ↓1.21</td>
<td>371</td>
<td>&gt;140</td>
<td>67/79</td>
</tr>
<tr>
<td>Hicks et al.[90] 34 (144)</td>
<td>LPV/r 400/200’ +NVPi +2 NRTIs j</td>
<td>4.0 ↑1.07</td>
<td>372</td>
<td>&gt;108</td>
<td>74/93</td>
</tr>
<tr>
<td>34 (144)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a d4T and 3TC added from week 3.
b d4T and 3TC were administered nonblind.
c Combined data from group I.
d Data estimated from a graph.
e Combined data from group II.
f Poster.
g OT analysis data.
h Patients received separate capsules of LPV and r until coformulated capsules became available. LPV was given nonblind while r was given double-blind.
i From day 15 patients received NVP od for 2 weeks and bid thereafter.
j On day 15 NRTI regimen was changed to include ≥1 novel NRTI. Actual drugs not reported.
k Abstract and poster.
d4T = stavudine 40; ITT = intent-to-treat analysis; LLQ = lower limit of quantitation; NNRTI = non-nucleoside reverse transcriptase inhibitor; NR = not reported; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine 200; od = once daily; OT = on-treatment analysis; pts = patients; tid = three times daily; viral load = HIV-1 RNA level; 3TC = lamivudine 150; ↓ indicates decrease; ↑ indicates increase; *p = 0.01; **p = 0.002; ***p < 0.001 vs comparator regimen.

A phase III trial conducted thus far compared the efficacy of lopinavir/ritonavir- versus nelfinavir-containing antiretroviral regimen in HIV-infected adult patients (table V).[68] The efficacy of lopinavir/ritonavir coformulation was also assessed in two prospective, nonblind, noncomparative studies (the EAP and the ATU programme) involving >11 000 HIV-1-infected patients who had failed to respond to and/or were intolerant to various combinations of available antiretroviral agents. In these patient populations lopinavir/ritonavir-based regimens were evaluated as salvage therapy options.[74-78]

5.1.1 Antiretroviral Therapy-Naive Patients

Dose-Comparison Trial

Antiretroviral therapy-naive HIV-infected adults (age ≥18 years) were enrolled sequentially into two groups (group I excluded patients coinfected with hepatitis B and/or C virus [HBV/HCV]). Patients were then randomised to receive one of two dosage regimens of lopinavir/ritonavir (group I: 200/100mg or 400/100mg twice daily; group II: 400/100mg or...
400/200mg twice daily) in combination with lamivudine and stavudine (table V). Inclusion criteria were based predominantly on plasma HIV-1 RNA levels with no CD4+ cell count restriction; hence patients in this phase II study presented with a relatively high mean plasma viral load and a wide range of immunological responsiveness at baseline.

In the initial 48-week study, the lopinavir/ritonavir combinations reduced plasma HIV-1 RNA and increased mean CD4+ cell counts when combined with two commonly used NRTIs in antiretroviral therapy-naive patients (table V). Overall, the mean reduction in plasma HIV-1 RNA from baseline was 2.23 log_{10} copies/mL, and 85% and 92% of patients (ITT and OT analyses) had <400 copies/mL at the end of the study. Median time required for plasma viral load to decrease below 400 and 50 copies/mL was 6–8 and 10–12 weeks, respectively. Patients with baseline viral load >5 log_{10} copies/mL generally required more time to achieve a viral load <400 copies/mL than patients with baseline values of <5 log_{10} copies/mL (12 vs 4 weeks). However, all lopinavir/ritonavir-based regimens showed sustained viral suppression at and beyond 20 weeks of treatment regardless of baseline viral load. Patients in all treatment groups also showed a substantial increase (i.e., 44–84%) in the mean CD4+ cell count at week 48 (table V).

In the extension of this study, after the 48-week trial the dosage of lopinavir/ritonavir was changed to 400/100mg twice daily in all patients and the study was continued in a nonblind fashion. The follow-up results to week 204 showed continued suppression of viral load below LLQ in a substantial proportion of patients by both ITT and OT analyses (figure 2).

The effects of the lopinavir/ritonavir-based treatment on viral load and CD4+ cell count were not influenced by patient baseline virological or immunological status. For example, after 144 weeks of treatment with the lopinavir/ritonavir-based regimen, the proportion of patients with plasma HIV-1 RNA levels of <50 copies/mL was similar between patients with higher (≥5 log_{10} copies/mL) and lower (<5 log_{10} copies/mL) baseline viral loads (92% vs 100% and 80% vs 73%; OT and ITT analyses, respectively). Likewise, similar proportions of patients with higher (≥200 cells/µL) and lower (<200 cells/µL) baseline CD4+ cell counts had their viral load reduced below 50 copies/mL (98% vs 94% and 72% vs 83%; OT and ITT analyses, respectively). At week 204, the Kaplan-Meier estimate of the proportion of patients still maintaining virological response was 84.1%.

The immunological status of patients who remained on treatment with lopinavir/ritonavir-based antiretroviral regimen continued to improve steadily and at week 204 the mean increase from baseline in their CD4+ cell count was 440 cells/µL. Only 8 of 79 patients remaining on-treatment at weeks 144–156 had an increase from baseline in CD4+ cell count of <100 cells/µL. However, the final values in all eight patients were >500 cells/µL. The rate and the amount of increase in CD4+ cell count appeared to be consistent regardless of patient baseline immune status. Even patients with the most advanced disease (baseline CD4+ cell count <50 cells/µL; n = 17) achieved a mean increase of 423 cells/µL in CD4+ count at week 204.

In Comparison with Nelfinavir

A large phase III study compared the efficacy of lopinavir/ritonavir with the PI nelfinavir in combination with two NRTIs, lamivudine and stavudine, in 653 antiretroviral therapy-naive adult (age ≥12 years) patients with HIV infection (table V). Lopinavir/ritonavir demonstrated significantly greater suppression of plasma HIV-1 RNA levels than nelfinavir, starting from week 20 (LLQ <400 copies/mL) and week 32 (LLQ <50 copies/mL) and persisting through weeks 48 and 60 (table V). Patients treated with lopinavir/ritonavir showed only a slightly higher increase from baseline.
Table VI. Comparative efficacy of lopinavir/ritonavir versus nelfinavir in relation to baseline hepatitis status. Week 60 results from a randomised, double-blind, multicentre trial in antiretroviral therapy-naive HIV-1-positive adults.\textsuperscript{[87]} On-treatment analyses are presented.

<table>
<thead>
<tr>
<th>Baseline hepatitis status(^{a})</th>
<th>No. of patients (% of total)</th>
<th>Mean age (y)</th>
<th>M/F</th>
<th>Plasma viral load (log(_{10}) copies/mL)</th>
<th>CD4+ count (cells/µL)</th>
<th>Patients with plasma viral load below LLQ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>baseline mean increase &lt;400 copies/mL &lt;50 copies/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>57 (17.5)</td>
<td>41</td>
<td>82/18</td>
<td>4.8</td>
<td>283</td>
<td>246(^{d})</td>
</tr>
<tr>
<td>Negative</td>
<td>269 (82.5)</td>
<td>38</td>
<td>79/21</td>
<td>4.9</td>
<td>255</td>
<td>247(^{d})</td>
</tr>
<tr>
<td>Positive</td>
<td>68 (21)</td>
<td>37</td>
<td>78/22</td>
<td>5.0</td>
<td>244</td>
<td>233(^{c})</td>
</tr>
<tr>
<td>Negative</td>
<td>259 (79)</td>
<td>37</td>
<td>81/16</td>
<td>4.9</td>
<td>261(^{c})</td>
<td>219(^{c})</td>
</tr>
</tbody>
</table>

\(\text{a}\) On enrolment, all patients were screened for hepatitis B surface antigen and anti-hepatitis C antibody. Patients were then classified as hepatitis positive if either test was positive.  
\(\text{b}\) All patients also received lamivudine 150mg and stavudine 40mg bid in a nonblind fashion.  
\(\text{c}\) Data estimated from a graph.  
\(\text{d}\) One patient did not have a baseline CD4+ cell count measurement.

bid = twice daily; F = female; LLQ = lower limit of quantitation; M = male; tid = three times daily; viral load = HIV-1 RNA level.

in the mean CD4+ cell count than patients treated with nelfinavir (table V).\[^{3}\] However, in patients with very low CD4+ cell counts at baseline (<50 cells/µL), lopinavir/ritonavir induced a significantly greater increase in the mean CD4+ cell count compared with nelfinavir after 60 weeks of treatment (266 vs 198 cells/µL; \(p < 0.05\)).\[^{84}\]

Treatment with the lopinavir/ritonavir-based triple regimen was equally as effective in women as in men with HIV-1 infection, as determined by the percentage of patients with <50 HIV-1 RNA copies/mL (83% vs 82% and 61% vs 65%; OT and ITT analyses, for respective sexes) and by the mean increase from baseline in CD4+ cell count (257 vs 244 cells/µL).\[^{86}\]

Patients receiving lopinavir/ritonavir-based triple therapy had a significantly greater probability of maintaining virological response at 48 and 60 weeks than recipients of nelfinavir-based regimen (84% vs 66% and 81% vs 65%, both \(p < 0.001\) between treatment regimens).\[^{86,84}\]

A subgroup of 125 patients (lopinavir/ritonavir = 57, nelfinavir = 68) in this study were coinfected with HBV/HCV.\[^{87}\] Baseline immunological, virological and demographic characteristics of HBV/HCV positive and negative patients were similar between the treatment groups (table VI).\[^{87}\]

After 60 weeks, on-treatment antiviral responses (at LLQ <400 and <50 HIV-1 RNA copies/mL) and immunological response rates (measured as increase in CD4+ cell count) of patients within lopinavir/ritonavir- and nelfinavir-treatment groups were similar in relation to patients’ baseline hepatitis status (table VI).\[^{87}\]

5.1.2 Antiretroviral Therapy-Experienced Patients

Single PI-Experienced, NNRTI-Naive Patients

A dose-comparison phase II trial investigated the efficacy of lopinavir 400mg coformulated with ritonavir 100 or 200mg twice daily for 144 weeks in 70 adult (age \(\geq 18\) years) HIV-1-infected patients who were experiencing virological failure (defined as plasma HIV-1 RNA level of 3–5 log\(_{10}\) copies/mL) with treatment regimen comprising a single PI, alone or combined with one or more NRTI (table V).\[^{67,85}\] The existing PI regimen of all patients was replaced with one of the two lopinavir/ritonavir dose combinations on day 1 of the study. All patients also received nevirapine (200mg once daily for 2 weeks from day 15, followed by 200mg twice daily thereafter) and had their baseline NRTI regimen changed on day 15 to include at least one NRTI they had not received previously. Ritonavir was administered in a double-blind fashion, whereas lopinavir, nevirapine and NRTIs were administered nonblind.\[^{67}\]

The lopinavir/ritonavir-based regimen induced rapid viral suppression with 80% of patients experiencing ≥1 log\(_{10}\) copies/mL reduction from baseline in plasma HIV-1 RNA levels or achieving a viral load of <400 copies/mL, within the first 2 weeks of treatment.\[^{67}\] These results were maintained at 48 weeks and for the duration of the study in patients who continued lopinavir/ritonavir-based salvage therapy (table V).\[^{85}\]
The susceptibility towards lopinavir, the principal component of the drug with antiretroviral activity, was variable in HIV-1 isolated from patients enrolled in this study. The baseline HIV-1 isolates were 0.7–26 (mean 2.8) times less susceptible to lopinavir than the wild-type HIV-1 (as determined by fold increase in IC₅₀). The initial viral load decline was independent of both the baseline HIV-1 IC₅₀ for lopinavir and the prior PI experience of the study participants.

Throughout the study and up to week 144, no statistically significant difference in the antiviral activity was recorded between the two lopinavir/ritonavir dose combinations. At week 144, more than half of all patients enrolled still had plasma HIV-1 RNA levels suppressed below 400 copies/mL (table V) and in almost half of them (49% overall) it was below 50 copies/mL.

The lopinavir/ritonavir-based salvage therapy induced a rapid improvement in CD4+ lymphocyte count and statistically significant increase from baseline was observed in both treatment groups at and after week 8 (p < 0.001). The mean overall increase from baseline in CD4+ cell count at week 144 was 211 cells/µL with no statistically significant difference between treatment groups observed at any time point (table V).

Multiple PI-Experienced, NNRTI-Naive Patients

A smaller randomised, nonblind trial in multiple PI-experienced (mean prior PIs = 3) but NNRTI-naive HIV-infected adult patients (n = 57; age >18 years) compared the efficacy of two lopinavir/ritonavir dose combinations (i.e. 400/100mg vs 533/133mg twice daily) in an antiretroviral regimen containing efavirenz 600mg once daily and NRTIs of the investigators’ choice over the 24-week period (results presented only in an abstract and a poster).

Upon enrolment all patients were randomised into two study arms (A and B) and had their current PI replaced with lopinavir/ritonavir 400/100mg which they received twice daily in combination with efavirenz and NRTIs (actual drugs not specified) for the first 13 days of the study. Preliminary pharmacokinetic analyses for lopinavir and efavirenz were performed in all patients at day 14. Following that, patients in arm A (n = 29) continued treatment with the same regimen until week 24, while the patients in study arm B (n = 28) had their lopinavir/ritonavir dosage increased to 533/133mg twice daily for the duration of the trial.

After 24 weeks, the study became noncomparative as all patients in study arm A converted to the 533/133mg twice-daily dosage of lopinavir/ritonavir. The rationale for the dose increase was provided by pharmacokinetic analyses performed at week 5 showing that efavirenz reduced lopinavir plasma concentrations achieved with lopinavir/ritonavir 400/100mg twice daily compared with historical data in HIV-infected adults receiving lopinavir/ritonavir without efavirenz (section 4.2.1 and table III).

Treatment with the lopinavir/ritonavir 533/133mg twice-daily regimen resulted in a similar degree of plasma viral load suppression (92% vs 80% of patients had plasma HIV-1 RNA <400 copies/mL; OT analysis) and a similar increase in the CD4+ cell count (41 vs 48 cells/µL) from baseline, to that with the 400/100mg regimen at week 24. In the extension of the study, treatment with the lopinavir/ritonavir 533/133mg twice-daily regimen maintained this level of viral load suppression up to week 72 (67% and 61% of the ITT population, and 88% and 81% of the OT population had HIV-1 RNA <400 and <50 copies/mL, respectively). The CD4+ cell count continued to improve and at week 72 the mean increase from baseline among patients on treatment was 126 cells/µL.

Baseline in vitro phenotypic and genotypic susceptibility to lopinavir of viral isolates had an important influence on virological response throughout the course of the study (section 2.3.2).

Multiple PI-Experienced, NNRTI-Experienced Patients with Virological Failure

The efficacy of lopinavir/ritonavir coformulation has also been evaluated through the prospective, nonblind, noncomparative EAP. This study recruited >11 000 HIV-1-infected adult patients from 35 countries with significant prior exposure to both PIs and NNRTIs. These patients had failed to respond to and/or were intolerant to combinations of other available antiretroviral agents and in many, disease stage was advanced at study enrolment (table VII). The bulk of the available data from the EAP are from four representative countries (i.e. Italy, Germany, Canada, and Spain) and are derived from posters and abstracts. Baseline demographic and disease characteristics of patients in each ‘national’ EAP were generally similar (table VII). The mean duration of follow-up ranged be-
Table VII. Overview of baseline demographic and disease characteristics of participants in the ATU programme and in the Expanded Access Program (EAP) in four representative countries

<table>
<thead>
<tr>
<th>Country of data origin (no. of evaluable pts)</th>
<th>Mean age (y)</th>
<th>M/F (%)</th>
<th>Clinical category according to CDC classification for HIV infection (% of pts)</th>
<th>Kamofsky score (mean)</th>
<th>Plasma HIV-1 RNA level</th>
<th>CD4+ cell count</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>A⁶</td>
<td>B⁷</td>
<td>C⁸</td>
<td>mean (log₁₀ copies/mL) ≥4 log₁₀ copies/mL (% of pts)</td>
</tr>
<tr>
<td>Germany (684) [76]</td>
<td>43.0</td>
<td>87/12</td>
<td>7.9</td>
<td>31.7</td>
<td>57.2</td>
<td>88.3</td>
</tr>
<tr>
<td>Italy (1265) [76]</td>
<td>39.9</td>
<td>68/24</td>
<td>22.0</td>
<td>24.7</td>
<td>39.1</td>
<td>91.6</td>
</tr>
<tr>
<td>Spain (1772) [77]</td>
<td>39.2</td>
<td>74/23</td>
<td>22.6</td>
<td>23.6</td>
<td>44.3</td>
<td>96.2</td>
</tr>
<tr>
<td>Canada (1256) [79]</td>
<td>42.6</td>
<td>91/8</td>
<td>17.6</td>
<td>35.5</td>
<td>42.0</td>
<td>88.4</td>
</tr>
<tr>
<td>ATU programme (3447)</td>
<td>42.0</td>
<td>80/20</td>
<td>16.8</td>
<td>31.9</td>
<td>51.3</td>
<td>4.66</td>
</tr>
</tbody>
</table>

a Unspecified data not presented; percentages from the EAP do not add up to 100.
b Asymptomatic or acute (primary) HIV or persistent generalised lymphadenopathy.
c Symptomatic, neither A nor C conditions.
d AIDS-indicator conditions.

ATU = Autorisation Temporaire d’Utilisation; CDC = Centers for Disease Control; F = female; M = male; pts = patients.

Between 4.5 [75] and 8.6 [76] months. In France the EAP was rapidly switched to an ATU programme in which potentially-lifesaving medications are made available to patients prior to their approval. [25, 78] Genotype analysis of viral isolates was performed at baseline in the ATU programme but not the EAP. In both studies, patients received lopinavir/ritonavir 400/100mg twice daily either in tablet or liquid form. The dosage was increased to 533/133mg if concomitant treatment included nevirapine or efavirenz.

In the EAP, >50% of patients achieved a viral load of ≤500 copies/mL (some data estimated from graphs). [74-77] When the virological response criteria were expanded to also include patients with ≥1 log₁₀ copies/mL reduction from baseline, an overall response was observed in ≈75% of patients (some data estimated from graphs). [74-77] Similarly, in the ATU programme, ≈72% of patients achieved virological response (defined as plasma HIV-1 RNA level <400 copies/mL or ≥1 log₁₀ copies/mL decrease from baseline) after 6-month treatment with lopinavir/ritonavir-based regimens. [25] Both studies showed a strong correlation between baseline CD4+ cell count, lopinavir mutation score and prior PI use and the virological response to the lopinavir/ritonavir-based treatment of HIV-1 infection (p < 0.01). [25]

An association between the lopinavir mutation score as well as the individual PI mutations (including lopinavir) present at baseline and the virological response to lopinavir/ritonavir was observed in the

Table VIII. Efficacy of lopinavir/ritonavir in antiretroviral therapy-naive and -experienced children with HIV-1 infection. All patients (pts) received lopinavir/ritonavir 300/75 mg/µL twice daily in oral solution. Week 72 results from a nonblind, phase I/II study. [26] Intent-to-treat analyses are presented

<table>
<thead>
<tr>
<th>Antiretroviral therapy-related pts statusa</th>
<th>No. of pts</th>
<th>Mean age (y)</th>
<th>M/F (%)</th>
<th>Plasma viral load (log₁₀ copies/mL) at baseline</th>
<th>CD4+ cell count (cells/µL) mean increase &lt;400 copies/mL &lt;50 copies/mL below LLQ (%)</th>
<th>Pts with plasma viral load below LLQ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naiveb</td>
<td>44</td>
<td>4.8</td>
<td>41/59</td>
<td>4.9</td>
<td>920⁺ 387</td>
<td>89 71</td>
</tr>
<tr>
<td>Experiencedc</td>
<td>56</td>
<td>5.7</td>
<td>45/55</td>
<td>4.5</td>
<td>773 435</td>
<td>68 55</td>
</tr>
</tbody>
</table>

a Pts were defined as naive or experienced if they had received ≤3 months or >3 months of prior antiretroviral therapy and ≤1 week or >1 week of treatment with lamivudine, respectively.
b Pts received additional treatment with stavudine and lamivudine.
c Pts received additional treatment with nevirapine and one or two NRTIs of the investigator’s choice. [26] Dosage of nevirapine was 7 mg/kg bid for pts aged 6m to 8y or 4 mg/kg bid for older pts. [15]  

F = female; LLQ = lower limit of quantitation; M = male; NRTI = nucleoside reverse transcriptase inhibitor; viral load = HIV-1 RNA level;  
⁺ p < 0.05 between patient groups.
Spanish EAP\textsuperscript{[23]} and the ATU\textsuperscript{[24,25,90]} (see section 2.3.3 for details).

5.2 In Children

The clinical efficacy of lopinavir/ritonavir liquid formulation has been evaluated in a nonblind, phase I/II study in antiretroviral therapy-naive (≤3 months of prior antiretroviral therapy and ≤1 week of treatment with lamivudine; n = 44) and -experienced (n = 56) patients (children aged between 3 months and 12 years) infected with HIV-1 (presented as a poster\textsuperscript{[26]}). All patients were initially randomised to receive lopinavir/ritonavir 230/57.5 mg/m\textsuperscript{2} (n = 49) or 300/75 mg/m\textsuperscript{2} (n = 51) in oral solution once every 12 hours. These dosages were chosen to mimic the exposure to lopinavir achieved in adults after administration of lopinavir/ritonavir 400/100mg twice daily. After the week 3 pharmacokinetic, tolerability and efficacy analyses, dosage of the study drug was changed to 300/75 mg/m\textsuperscript{2} twice daily for all study participants. In addition to lopinavir/ritonavir, all patients also received lamivudine and stavudine (antiretroviral therapy-naive patients), or nevirapine and 1–2 NRTI agents of the investigator’s choice (antiretroviral therapy-experienced patients) [nevirapine regimen was 7 or 4 mg/kg twice daily, for patients aged 6 months to 8 years or for older children, respectively;\textsuperscript{[15]} dosages of NRTIs, including lamivudine and stavudine, were not specified].

Demographic characteristics and the virological status at baseline of patients in both groups in this study were similar (table VIII). However, patients naive to antiretroviral drug treatment had higher CD4+ cell counts at baseline than the experienced patients (p < 0.05) [table VIII]. Most patients in this study had acquired HIV-1 infection in the perinatal period (98% and 95% of antiretroviral therapy-naive and -experienced patients, respectively).

After 72 weeks, lopinavir/ritonavir-based treatment regimens adequately suppressed plasma HIV-1 RNA levels in most patients, although overall responses tended to be lower in antiretroviral therapy-experienced patients (table VIII). A larger proportion of PI-naive, NRTI-experienced patients (n = 32) had viral load suppressed below 400 copies/mL than patients previously treated with both PI and NRTI agents (n = 24) [81% vs 50%; p-value not reported]. The immune status of patients in each group continually improved throughout the study and at week 72 the mean increase from baseline in CD4+ cell count was 11.2%, 9.2% and 7.7% in antiretroviral therapy-naive, PI-/NRTI-experienced, and PI-naive/NRTI-experienced patients, respectively.\textsuperscript{[26]}

Antiviral activity of lopinavir/ritonavir in PI-experienced patients was influenced by baseline phenotype resistance of HIV-1 isolates (section 2.3.4).\textsuperscript{[26]}

6. Tolerability

It is difficult to precisely attribute causality of adverse events to treatment with the lopinavir/ritonavir coformulation as associations are confounded by patients’ concomitant therapies and the severity of their illness.

The tolerability of the lopinavir/ritonavir coformulation in combination with other antiretroviral agents has been evaluated in both antiretroviral therapy-naive\textsuperscript{[26,80,84,91]} and -experienced\textsuperscript{[20,26,74-77,85-91]} patients infected with HIV-1, in comparative\textsuperscript{[20,26,80,84,85,91]} and noncomparative\textsuperscript{[74-77]} clinical trials, and separately in adults\textsuperscript{[20,74-77,80,84,85,91]} and children.\textsuperscript{[26]} Overall in these trials and patient populations lopinavir/ritonavir appeared to be well tolerated, with low rates of drug-related discontinuation of therapy (table IX).\textsuperscript{[84,91]}

6.1 In Adults

6.1.1 Comparative Trials

Tolerability of lopinavir/ritonavir has been evaluated in 553 HIV-1-infected adults from four randomised, comparative, phase II/III clinical trials (see section 5.1 and table V for study details; see table IX for summary of adverse events and laboratory abnormalities).\textsuperscript{[20,80,84,85,91]}

The tolerability profile of lopinavir/ritonavir 400/100mg twice daily in the phase III trial was generally similar to that of nelfinavir 750mg three times daily (table IX).\textsuperscript{[91]} The most frequently reported adverse event of at least moderate severity was diarrhoea in both phase II\textsuperscript{[80,85,91]} and phase III\textsuperscript{[91]} clinical trials and in both antiretroviral therapy-naive\textsuperscript{[80,91]} and -experienced\textsuperscript{[83,91]} patients. Other less common events included other gastrointestinal (GI) disturbances, asthenia, headache and skin rash.\textsuperscript{[91]}

Circumoral paraesthesia has not been reported with lopinavir/ritonavir administration. In some instances the incidence of specific adverse events in dose-
### Table IX. Incidence of adverse events of at least moderate severity (causality not established) and of grade 3/4 laboratory abnormalities in four randomised, comparative phase II/III lopinavir/ritonavir (LPV/r) clinical trials in adult patients (pts) with HIV-1 infection [20,80,84,85,91]

<table>
<thead>
<tr>
<th>Results (% of pts)</th>
<th>Phase III ARV-naive pts</th>
<th>Phase II ARV-naive pts</th>
<th>Phase II single PI-exp pts</th>
<th>Phase II multiple PI-exp pts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Phase III ARV-naive pts</td>
<td>Phase II ARV-naive pts</td>
<td>Phase II single PI-exp pts</td>
<td>Phase II multiple PI-exp pts</td>
</tr>
<tr>
<td></td>
<td>Phase III ARV-naive pts</td>
<td>Phase II ARV-naive pts</td>
<td>Phase II single PI-exp pts</td>
<td>Phase II multiple PI-exp pts</td>
</tr>
<tr>
<td></td>
<td>LPV/r+d4T+3TC</td>
<td>LPV/r+d4T+3TC</td>
<td>LPV/r+NVP+2 NNRTIs</td>
<td>LPV/r+EFV+NRTIs</td>
</tr>
<tr>
<td>(n = 326)</td>
<td>(n = 327)</td>
<td>(n = 100)</td>
<td>(n = 70)</td>
<td>(n = 57)</td>
</tr>
<tr>
<td>Adverse events</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>17</td>
<td>18</td>
<td>28</td>
<td>31</td>
</tr>
<tr>
<td>Nausea</td>
<td>7</td>
<td>5</td>
<td>16</td>
<td>3</td>
</tr>
<tr>
<td>Asthenia</td>
<td>4</td>
<td>3</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>4</td>
<td>3</td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3</td>
<td>2</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Headache</td>
<td>3</td>
<td>2</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Rash</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Laboratory abnormalities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (&gt;7.77 mmol/L)</td>
<td>11</td>
<td>6</td>
<td>22</td>
<td>31</td>
</tr>
<tr>
<td>Triglycerides (&gt;8.25 mmol/L)</td>
<td>11†</td>
<td>2</td>
<td>22</td>
<td>22</td>
</tr>
<tr>
<td>AST/ALT (&gt;5 x ULN)</td>
<td>6</td>
<td>5</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>Amylase (&gt;2 x ULN)</td>
<td>4</td>
<td>2</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Glucose (&gt;13.75 mmol/L)</td>
<td>2</td>
<td>2</td>
<td>2†</td>
<td>3</td>
</tr>
<tr>
<td>LPV/r-related therapy discontinuations</td>
<td>4</td>
<td>4</td>
<td>7†</td>
<td>6†</td>
</tr>
</tbody>
</table>

a Severity grades based on the Division of AIDS Grading Severity of Adult Adverse Events criteria.
b Phase II trials compared different dosages of lopinavir/ritonavir administered twice daily. The results from a trial in single PI-experienced pts are presented for the 400/100mg cohort only, with the exception of the combined results for week 96 data. In the extension phases, after 48 and 24 weeks, of the respective trials in the ARV-naive and the multiple PI-experienced pts, all participants received lopinavir/ritonavir 400/100mg and 533/133mg, respectively, twice daily.
c Combined results for the LPV/r 400/100mg and 400/200mg cohorts at week 96.
d Week 48 data.
e Week 144 data.
f Determination of laboratory values were performed without regard to fasting.
g Week 72 data.
h Data from Ruane et al.
i Including one death of unknown cause 10 days after thoracic spinal surgery with perioperative myocardial infarction.

Comparison phase II trials was higher than in the phase III trial. This may be a consequence of a longer follow-up in the phase II than the phase III trial (204 or 144 vs 60 weeks) as well as of the addition of specific NNRTIs (nevirapine or efavirenz) to the treatment regimens in particular phase II trials (see table IX for details). The tolerability results from these phase II trials could have been also confounded by the use of different dosages of lopinavir/ritonavir in the initial, dose-comparison (i.e. 200/100mg, 400/100mg, 400/200mg or 533/133mg twice daily; see section 5.1 and table V for study details) and the trial extension, non-comparative phases (i.e. 400/100mg or 533/133mg twice daily) and by the smaller patient populations evaluated in phase II trials than in the phase III trial (table IX).

Over 60 weeks of treatment in the phase III study, 7% of patients (antiretroviral therapy-naive) in the lopinavir/ritonavir and nelfinavir groups had adverse events consistent with changes in body fat composition. In the lopinavir/ritonavir group these changes included lipodystrophy, obesity and abdominal enlargement (2% each), and Cushingoid ap-
pearance, multiple lipomas and gynaecomastia (≤1% each). None of these changes were associated with grade 3/4 lipid elevations.¹⁹¹

In three dose-comparison, phase II trials, changes in body fat composition occurred in 12% (week 144), 20% (week 96) and 7% (week 48) of antiretroviral therapy-naive, single PI- and multiple PI-experienced patients, respectively.¹⁹¹

In all comparative, phase II/III clinical trials, lopinavir/ritonavir administration was associated with marked laboratory abnormalities (table IX), with grade 3/4 lipid (total cholesterol and triglycerides) elevations being the most common.¹²⁰,⁶⁸,⁶⁹,⁹¹

Both abnormalities tended to occur early in the course of treatment, remained stationary over time and were more common in patients with prior PI experience or higher baseline lipid levels However, they were a rare cause of study drug discontinuations and responded well to treatment with lipid-lowering agents (but see section 4.1).¹⁹¹

In the phase III trial, laboratory abnormalities occurred with similar frequency in both treatment groups (table IX), with the exception of grade 3/4 elevations in triglycerides levels, which occurred more frequently in the lopinavir/ritonavir than in the nelfinavir group (11% vs 2%; p < 0.001). Importantly, though, grade 3/4 triglyceride elevations were not associated with development of pancreatitis or discontinuation of treatment in patients receiving either drug.¹⁹¹

It should be noted that in the phase II/III trials the measurements were taken without regard to fasting.⁸⁴,⁹¹

The tolerability profile of lopinavir/ritonavir was similar in HBV/HCV positive and negative patients with HIV-1 infection (see section 5.1.1 and table VI for study details).⁶⁷ The incidence of grade 3/4 laboratory abnormalities through week 60 were similar in both patient groups, although ALT elevation (>5-fold upper limit of normal [ULN]) was significantly more frequent in HBV/HCV positive than in hepatitis negative patients (12% vs 3%; p < 0.05).⁸⁷ No patients discontinued treatment with lopinavir/ritonavir because of an abnormal liver function test or a diagnosis of clinical hepatitis.⁸⁷

6.2 In Children

The liquid formulation of lopinavir/ritonavir 300/75 mg/m² administered twice daily was very well tolerated by antiretroviral therapy-naive (n = 44) and -experienced (n = 56) HIV-1-infected children, with only one lopinavir/ritonavir-related discontinuation of the treatment up to week 72 (pancreatitis in a child with elevated baseline amylase levels).²⁶

The incidence of adverse events of at least moderate severity and of probable or possible relationship to lopinavir/ritonavir was low; the most commonly reported adverse event occurring in 2% of patients was skin rash; allergic reactions, fever, viral infections, constipation, hepatomegaly, pancreatitis, vomiting, dry skin and taste perversion all occurred in 1% of patients.²⁶ Development of lipodystrophy was not reported in this study.
Biochemical abnormalities of grade 3/4 severity were also infrequent occurring in 6% (amylase >2.5xULN), 5% (AST/ALT >10xULN) and ≤3% (total bilirubin >2.9xULN, total cholesterol >7.7 mmol/L, triglycerides >8.25 mmol/L and pancreatic amylase >2xULN) of patients.  

7. Pharmacoeconomic Analyses

Thus far, two pharmacoeconomic models have been used to estimate the 60-week, 5-year and lifetime cost consequences of initiating antiretroviral therapy with lopinavir/ritonavir versus nelfinavir as the PI component in the triple regimen (in combination with lamivudine and stavudine). Both models utilised the results from a phase III study (section 5.1.1) in 625 antiretroviral therapy-naive HIV-infected patients and are reported as abstracts. The benefit of 22.1% higher 60-month response rate (at <400 HIV-1 RNA copies/mL) with lopinavir/ritonavir compared with nelfinavir conveyed a potential net cost savings (calculated in 2002 $US) of $US1454.14 per patient per 60 months of treatment in a decision-tree cost-analysis model. The acquisition costs for both drugs were assumed equal, the cost of therapy included antiretroviral drugs, clinical visits and, for patients who failed to respond to treatment, drug resistance testing, additional monitoring and treatment of AIDS-related events. When the regimen for patients who failed to respond to therapy was changed to two PIs plus two NRTIs, a PI plus an NNRTI plus two NRTIs, or a PI plus two NRTIs, the estimated cost savings per patient were $US2704.38, $US1928.46, and $US838.35, respectively, over 60 months.

In a cost-utility analysis, potential 5-year cost savings per patient were estimated to be $US4011 for lopinavir/ritonavir compared with nelfinavir, assuming an acquisition cost of $US18 per day for either drug and an estimated 5-year treatment response rate of 26% and 23% for each regimen, respectively. The estimated incremental cost-effectiveness ratio was $US3423 per quality-adjusted life-year (QALY) for lopinavir/ritonavir versus nelfinavir, which is comparable to values calculated for generic antihypertensive medications. As the second model also predicted median survival of 13.3 and 12.8 years, respectively, for patients initiating therapy with lopinavir/ritonavir and nelfinavir, the lifetime benefit of the former treatment was estimated at $US18 899 per QALY compared with the latter treatment. In the second model currency years were not stated, nor were discount rates mentioned.

8. Dosage and Administration

Coformulated lopinavir/ritonavir is available for oral administration in capsule (133.3mg lopinavir and 33.3mg ritonavir) and liquid (80/20 mg/mL) formulations. The recommended dosage for adults, in the US, for the treatment of HIV-1 infection is 400/100mg (three capsules or 5mL oral solution) twice daily. In children aged 6 months to 12 years, the recommended dosage of the oral solution (in combination with lamivudine and stavudine). Both models utilised the results from a phase III study (section 5.1.1) in 625 antiretroviral therapy-naive HIV-infected patients and are reported as abstracts. The benefit of 22.1% higher 60-month response rate (at <400 HIV-1 RNA copies/mL) with lopinavir/ritonavir compared with nelfinavir conveyed a potential net cost savings (calculated in 2002 $US) of $US1454.14 per patient per 60 months of treatment in a decision-tree cost-analysis model. The acquisition costs for both drugs were assumed equal, the cost of therapy included antiretroviral drugs, clinical visits and, for patients who failed to respond to treatment, drug resistance testing, additional monitoring and treatment of AIDS-related events. When the regimen for patients who failed to respond to therapy was changed to two PIs plus two NRTIs, a PI plus an NNRTI plus two NRTIs, or a PI plus two NRTIs, the estimated cost savings per patient were $US2704.38, $US1928.46, and $US838.35, respectively, over 60 months.

In a cost-utility analysis, potential 5-year cost savings per patient were estimated to be $US4011 for lopinavir/ritonavir compared with nelfinavir, assuming an acquisition cost of $US18 per day for either drug and an estimated 5-year treatment response rate of 26% and 23% for each regimen, respectively. The estimated incremental cost-effectiveness ratio was $US3423 per quality-adjusted life-year (QALY) for lopinavir/ritonavir versus nelfinavir, which is comparable to values calculated for generic antihypertensive medications. As the second model also predicted median survival of 13.3 and 12.8 years, respectively, for patients initiating therapy with lopinavir/ritonavir and nelfinavir, the lifetime benefit of the former treatment was estimated at $US18 899 per QALY compared with the latter treatment. In the second model currency years were not stated, nor were discount rates mentioned.

Lopinavir/ritonavir coformulated capsules and oral solution should be stored refrigerated (at 2–8°C) until dispensed and used within 2 months after reaching room temperature (up to 25°C). The drug is indicated for use only in combination with other antiretroviral agents. When coadministered with either nevirapine or efavirenz (and probably with amprenavir), the dosage of lopinavir/ritonavir should be increased by 33% (i.e. to 533/133mg and 300/75 mg/m², in adults and children [aged <12 years], respectively, twice daily) to achieve therapeutic lopinavir plasma concentrations. Appropriate dosages of amprenavir, saquinavir and indinavir when administered in combination with lopinavir/ritonavir have not yet been established.

As lopinavir and ritonavir are both metabolised principally by the liver (section 3.3) and the pharmacokinetic properties of the coformulated drugs have not been established in patients with hepatic impairment (e.g. patients with AST/ALT levels ≥2.5[83,84] or ≥3-fold[85] the ULN were excluded from randomised, double-blind, multicentre clinical trials), the drug should be administered with caution in this patient population. Since <3% of the lopinavir dose is excreted unchanged in the urine after multiple-dose administration of lopinavir/ritonavir.
navir (section 3.4), the impact of renal insufficiency on lopinavir elimination is likely to be minimal.

A number of clinically important drug interactions have been reported with lopinavir/ritonavir (section 4), necessitating dosage adjustments of lopinavir/ritonavir and/or the interacting drugs (section 4.2, table III and IV). Several drugs are contraindicated in patients receiving the coformulation (table II and section 4.1).

Data on lopinavir/ritonavir use in pregnant women are currently not available and the drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In the US, lopinavir/ritonavir is classified under pregnancy category C.

Whether lopinavir is secreted in human milk is unknown, although this has been demonstrated in studies in rats. Nevertheless, HIV-infected mothers receiving lopinavir/ritonavir should not breast-feed to avoid risking both serious adverse reactions in and postnatal transmission of HIV to their nursing infants.

As increased spontaneous bleeding has been reported in patients with haemophilia A and B receiving PIs (despite the lack of evidence of a causal relationship), caution should be exercised when administering lopinavir/ritonavir to this patient group.

9. Place of Lopinavir/Ritonavir in the Management of HIV Infection

According to estimates from the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the WHO, 37 million adults and 3 million children (aged <15 years) were living with HIV at the end of 2001. This >50% higher than the figures projected by WHO in 1991. In 2001 an estimated 5 million people became infected with HIV-1 and 3 million died from HIV/AIDS globally, despite the use of antiretroviral therapy which reduced HIV-1- and AIDS-related deaths in developed countries.

The pandemic of HIV-1 infection and its fatal prognosis emphasise the need for effective antiretroviral therapy. The use of agents targeting HIV-1 reverse transcriptase has been limited by the emergence of treatment-limiting toxicities (of both NRTIs and NNRTIs), development of resistant mutants (mostly with NNRTIs) and the inability to provide adequate long-term suppression of viral replication (NRTIs).

On the other hand, inhibitors of HIV-1 protease, another essential viral enzyme, can effectively suppress viral replication (decrease the plasma viral load) and induce substantial immune system recovery (increase the CD4+ cell count). However, their use is generally limited by modest oral bioavailability and short $t_{1/2}$ producing low $C_{\text{trough}}$ and requiring frequent administration of high doses (i.e. large number of ‘pills’) to achieve antiretroviral efficacy in vivo. The downside of the latter is development of significant adverse events which, coupled with strict dietary restrictions and the high pill burden of PIs, may compromise patients’ adherence to the PI-based treatment regimens.

A variety of antiretroviral drugs, approved by the US FDA, are currently available for the treatment of HIV-1 infection. They are classified according to their mechanism of action as either NRTIs (e.g. abacavir, didanosine, lamivudine, stavudine, tenofovir disoproxil, zalcitabine, zidovudine), NNRTIs (e.g. delavirdine, efavirenz, nevirapine) or PIs (e.g. amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir). The best treatment results, in terms of both the clinical outcomes and surrogate markers, are achieved with regimens containing three or more antiretroviral drugs. The most commonly recommended triple combination antiretroviral drug regimens include a dual NRTI plus either a PI (PI-triple), an NNRTI (NNRTI-triple) or a third NRTI (triple-NUC).

Pharmacokinetic enhancement by low-dose ritonavir has been previously shown to produce sustained plasma concentrations of PIs, including lopinavir, in excess of those required to completely (i.e. below LLQ) suppress viral replication. This pharmacological ‘boost’ also reduces the dosage and administration frequency of PIs in combined regimens. Coformulated lopinavir/ritonavir has been developed to maximise these pharmacokinetic benefits and to improve patient compliance by the more convenient (twice-daily) administration regimen, and is available in capsule and liquid formulations. Coformulated lopinavir/ritonavir is currently regarded as a first-choice agent for the treatment of patients with HIV-1 infection in combination with other antiretroviral agents.

In the US and Europe, the lopinavir/ritonavir coformulation is approved for use in combination
with other antiretroviral agents for the treatment of HIV-1 infection in both antiretroviral therapy-naive and -experienced patients (section 8). The optimal lopinavir/ritonavir dose combination is 400/100mg in a twice-daily regimen, administered with moderate-to-high fat content meals (section 3.1.1 and section 8) as determined in single- and multiple-dose pharmacokinetic studies in adults (both healthy volunteers and HIV-1-infected patients).

The current treatment guidelines strongly recommend the use of coformulated lopinavir/ritonavir in combination with two NRTIs as a first-line option for the treatment of HIV-1 infection in patients with no or limited prior antiretroviral drug experience.

The effects of lopinavir/ritonavir on primary clinical endpoints of HIV-1 infection (disease progression to AIDS and death) have not yet been studied. However, lopinavir/ritonavir-based triple and quadruple antiretroviral drug regimens provide effective suppression of plasma HIV-1 load (below LLQ) and a sustained immunological response (measured by increasing CD4+ cell counts), as confirmed in randomised, double-blind, multicentre clinical trials in both antiretroviral therapy-naive and -experienced adults (see section 5.1.1 and 5.1.2, and table V for details) and nonblind trials in ‘experienced’ adults (section 5.1.2) and children (section 5.2).

Studies comparing the therapeutic efficacy of lopinavir/ritonavir with that of other antiretroviral agents are sparse. In the only comparative phase III study published thus far, lopinavir/ritonavir in combination with lamivudine and stavudine showed significantly greater and more durable suppression of viral load than nelfinavir combined with the same two NRTIs (table V and section 5.1.1). Likewise, lopinavir/ritonavir induced significantly greater immune system recovery than nelfinavir, in patients with baseline CD4+ cell counts <50 cell/µL. A large, randomised, nonblind, multicentre, phase IV clinical trial is currently underway to compare the efficacy and safety of ritonavir-boosted lopinavir- versus saquinavir-based treatment regimens in HIV-1-infected patients (n = 326) who are naive or experienced to prior PI use. Comparative studies of ritonavir-boosted PIs (including lopinavir/ritonavir) versus NNRTIs would further aid decisions in selecting the best regimen for the treatment of HIV-1 infection.

The lopinavir/ritonavir-based PI-triple regimens appear to have greater potential for long-term success in the treatment of antiretroviral therapy-naive HIV-1-infected patients than other triple combination antiretroviral regimens (i.e. other PI-triple, NNRTI-triple and triple-NUC). A systematic review of 23 clinical trials, involving 19 such triple regimens in 3257 antiretroviral therapy-naive patients, estimated that, after 48 weeks of treatment, 45–51% of enrolled patients would still have plasma HIV-1 RNA levels ≤50 copies/mL, whereas, for the same timepoint and level of suppression, the lopinavir/ritonavir-based triple regimens are generally effective in 67–100% (ITT analysis) of ‘naive’ patients with similar baseline characteristics (e.g. median plasma viral load and CD4+ cell count). This high level of viral suppression in ‘naive’ patients has been maintained with the lopinavir/ritonavir-based triple regimen even after 4 years of therapy (section 5).

Thus far, the emergence of resistance to antiretroviral agents, including PIs, has been one of the greatest obstacles to the successful long-term treatment of HIV-1 infection. Incomplete suppression of viral replication during therapy fosters the emergence of resistant virus strains, leading to a resurgence of high-level replication and virological failure. Improved suppression of viral replication (i.e. achieved more rapidly and sustained for longer time) by the lopinavir/ritonavir-based regimens appears to prevent or delay development of drug resistance to lopinavir and cross-resistance to other PIs. This is reflected in the absence and low percentage of mutant HIV-1 strains with resistance to lopinavir (section 2.3.2 and 2.3.2). Comparative studies of lopinavir/ritonavir in antiretroviral therapy-naive and -experienced patients, respectively, to date (section 2.3). However, these observation await further confirmation from long-term studies that will incorporate HIV-1 genotyping at baseline.

Lopinavir/ritonavir-based regimens have demonstrated better virological response in patients harbouiring HIV-1 with five or less PI mutations than in patients carrying HIV-1 with more than five PI mutations associated with reduced susceptibility to lopinavir (section 2.3.2 and 2.3.2). This suggests that five PI resistance mutations represent the point at which clinically relevant reduction of sensitivity to lopinavir begins to occur. The correlation of virological response to baseline lopinavir phenotype and mutation score observed in these studies suggests that baseline genotype and/or phenotype testing may be beneficial in optimising the use of the lopinavir/ritonavir coformulation for
the treatment of HIV-1 infection in PI-experienced patients.

The lopinavir/ritonavir-based triple regimens appear to be equally effective in women and men with HIV-1 infection (section 5.1.1). This is important as recent reports indicate a dramatic rise in HIV-1 infection rates in women worldwide. According to the UNAIDS, almost one-third of all de novo acquired infections in the US now occur in women.

Similarly, the baseline hepatitis B/C status of HIV-positive adults (both men and women) does not appear to modify the effectiveness of the lopinavir/ritonavir-based PI triple regimens. However, treatment should be administered with caution in patients with hepatic impairment, as both lopinavir and ritonavir are metabolised principally in the liver (section 3.3) and their pharmacokinetic properties in this patient population are not yet established (section 3.5 and 8).

A number of clinically important drug interactions have been reported with lopinavir/ritonavir (section 4), necessitating dosage adjustments of lopinavir/ritonavir and/or the interacting drugs (section 4.2, table III and IV). Several drugs are contraindicated in patients receiving the coformulation (table II and section 4.1).

Intravenous use of illicit drugs and ‘needle-sharing’, is frequent among HIV-positive individuals and represents the second most common route of HIV-1 infection transmission globally (estimated 5–10% of total HIV transmissions). The methadone maintenance programmes are a form of treatment of opioid abuse and dependence. Recent reports suggested that lopinavir/ritonavir could be the preferred antiretroviral agent for use in HIV-1-infected patients participating in these programmes because the coformulation neither changes the methadone dosage requirements nor precipitates opioid withdrawal symptoms (unlike nevirapine and efavirenz) [section 4.2.2].

Mycobacterial tuberculosis is an AIDS-defining condition in patients with laboratory evidence of HIV-1. Coadministration of the antimycobacterial agent rifampicin with lopinavir/ritonavir at standard dosages is not recommended because of pharmacokinetic interactions leading to subtherapeutic lopinavir exposure and possible development of resistance (see section 4.1 for details). However, appropriate lopinavir/ritonavir dosage adjustment (section 4.1) in conjunction with therapeutic drug monitoring may permit concurrent use of rifampicin for the treatment of tuberculosis in patients with HIV-1 infection.

Antiretroviral therapy can be used to effectively decrease levels of HIV-1 RNA in both plasma and the anatomical sanctuary sites such as the genital tract and CSF, which have been described as viral reservoirs. However, unlike other PIs such as indinavir and amprenavir, both lopinavir (section 3.2) and ritonavir penetrate poorly from the bloodstream into the seminal plasma or cervicovaginal secretions, allowing for incomplete suppression of viral replication and development of resistant viral strains in these body compartments. Consequently, the presence of resistant HIV-1 strains in the genital tract presents a risk to both the patient (from systemic virological failure through re-infection with HIV-1 strains resistant to current therapy) and his/her sexual partner(s) [of acquiring an infection with an HIV-1 strain that is potentially more difficult to treat]. It is, therefore, necessary to combine lopinavir/ritonavir with antiretroviral drugs known to penetrate well into the human genital tract (the NRTIs zidovudine, lamivudine, stavudine and abacavir, and the NNRTIs nevirapine and efavirenz) or the PIs indinavir and amprenavir. Penetration of lopinavir and ritonavir into CSF also appears to be very low (section 3.2).

In phase II/III clinical trials, lopinavir/ritonavir was well tolerated as indicated by the low rates of drug-related therapy discontinuations in both antiretroviral therapy-naive and -experienced patients (table IX). This is in contrast to ‘high-dose’ ritonavir, which has the highest adverse event-related drug discontinuation rate among PIs. The tolerability profile of lopinavir/ritonavir may be preferable to that of indinavir, which is associated with nephrolithiasis and is very similar to that of nelfinavir (table IX), except for the higher incidence of grade 3/4 triglycerides elevation observed with the coformulation in antiretroviral therapy-naive patients (section 6.1.1). The coformulation appears to be associated with marked hypertriglyceridaemia and hypercholesterolaemia more frequently in patients failing prior treatment with multiple PIs than in antiretroviral therapy-naive patients, as well as in patients with elevated baseline triglycerides and cholesterol levels (section 6.1.1 and table IX).
clinical significance of these lipid abnormalities, which have been associated with the use of PIs in general, lies in their predisposition for development of cardiovascular events and pancreatitis.\(^1\) Therefore, treatment with lopinavir/ritonavir should be accompanied by monitoring for lipid abnormalities and may require cautious use of lipid-lowering agents (see section 4.1 and 4.2.2 for possible drug interactions with the coformulation).

As with other PIs,\(^1\) the most common adverse events in adults, of at least moderate severity, associated with lopinavir/ritonavir are GI disturbances (diarrhoea being the most frequently reported) [table IX and section 6.1]. The other common adverse events (asthenia, headache and skin rash) tend to occur less frequently with lopinavir coformulated with ‘low-dose’ ritonavir (table IX) than with ‘high-dose’ ritonavir alone.\(^127,128\) Circumoral paraesthesia, a common adverse event and a cause of treatment discontinuation with ‘high-dose’ ritonavir,\(^127,128\) is not observed with the lopinavir/ritonavir coformulation.

In children, the incidence of adverse events associated with lopinavir/ritonavir of at least moderate severity appears to be low (section 6.2). In both adult and paediatric populations, serious adverse events (such as pancreatitis, myocardial infarction, lactic acidosis and hepatic failure) (section 6.1.2 and 6.2) have occurred infrequently during lopinavir/ritonavir therapy.

The use of PI drugs in the treatment of HIV-1 infection has been associated with development of lipid abnormalities (elevated serum cholesterol and triglyceride levels) as well as metabolic disorders including insulin resistance and diabetes mellitus, body fat redistribution (lipodystrophy), and cardiovascular disorders such as myocardial infarction.\(^129-137\) Lipodystrophy is of particular concern as many patients become reluctant to accept treatment with PIs because of their potential to induce cosmetic changes in body shape (e.g. loss of fat from the face and limbs, accumulation of visceral fat in the abdomen, breast enlargement and occasional formation of a ‘buffalo hump’).\(^129-131,135,138\) Development of Cushingoid appearance thus becomes an obvious stigma of HIV-1 infection and the antiretroviral treatment received for it. Changes in body fat composition have been observed in a small percentage of adult antiretroviral therapy-naive patients (7% over 60 weeks; section 6.1) receiving lopinavir/ritonavir-based treatment. However, it is possible that these findings may differ with wider clinical experience, as effects of disturbances in lipid metabolism tend to develop over time and should be actively monitored.

The cost effectiveness of the PI- and NNRTI-triple therapies in the management of HIV-1 infection have been previously well established (in comparison with no antiretroviral therapy or with mono-, dual- and triple-NUC therapies) in the US, Europe and Canada.\(^139-141\) Pharmacoeconomic data on lopinavir/ritonavir use in the treatment of HIV-1 infection are limited but the available analyses suggest a cost savings with its use in comparison with nelfinavir (section 7).

Although the acquisition costs of particular drugs may vary, coformulated lopinavir/ritonavir maintains the potential advantage of low ‘pill burden’ and ‘single-pill’ administration over the other PIs. At the recommended dosage for adults and adolescents (section 8) coformulated lopinavir/ritonavir is administered as three capsules twice daily. In contrast, recommended regimens of other PIs range from 5–8 capsules or tablets twice daily\(^127,142,143\) to 2–6 capsules three times per day\(^126,144\) Daily pill burden of lopinavir/ritonavir (six capsules) compares favourably with those of saquinavir\(^145,146\) and amprenavir\(^142,147\) (eight capsules each) but less favourably with indinavir (four capsules),\(^148-150\) in most clinically accepted regimens for PIs coadministered with a ‘low-dose’ ritonavir. The low pill burden of lopinavir/ritonavir is expected to improve adherence to the treatment regimen,\(^129\) whereas its administration in coformulated capsules eliminates the possibility that patients may take the active PI (lopinavir) without its pharmacokinetic enhancer (ritonavir). Consequently, administration of lopinavir/ritonavir in the same capsule reduces the risk of subtherapeutic lopinavir plasma concentrations and the possible development of viral resistance.

Like all other available therapies, lopinavir/ritonavir is, however, not a cure for AIDS and patients treated with this drug may still continue to develop illnesses associated with advanced HIV-1 infection, including opportunistic infections. Lopinavir/ritonavir has also not been shown to reduce the risk of transmission of HIV-1 infections to others through sexual contact or blood contamination.\(^151\) The safety and efficacy of lopinavir/ritonavir have not yet been studied in pregnant women and neonates.
In conclusion, coformulated lopinavir/ritonavir is a novel PI that, in combination with other antiretroviral agents, suppresses plasma viral load and enhances immunological status in therapy-naive-and-experienced patients with HIV-1 infection. Lopinavir/ritonavir appears equally effective in adults and children and in both sexes, although data in children are limited, and more effective than nelfinavir in antiretroviral therapy-naive patients. The coformulation is also suitable for ‘salvage’ therapy, because of its high barrier to development of resistance. Given its clinical efficacy, a tolerability profile in keeping with this class of drugs, a favourable resistance profile and easy-to-adhere-to administration regimen, coformulated lopinavir/ritonavir should be regarded as a first-line option when including a PI in the management of HIV-1 infection.

References


31. Paukstadt W. Improved HIV therapy with protease inhibitors (lopinavir/ritonavir) in antiretroviral-naive HIV+ patients: 48-week follow-up [abstract no. TuPeB4565]. 14th International AIDS Conference; 2002 Jul 7-12; Barcelona


44. Rapaport S, Maroldo-Connelly L, Patterson JB, et al. Lack of methadone dose alterations or withdrawal symptoms with lopinavir/ritonavir (Kaletra®) [abstract no. TuPeB 4539]. 14th International AIDS Conference; 2002 Jul 7-12; Barcelona, 400


65. Carr RA, Andre AK, Bertz RJ, et al. Concomitant administration of ABT-378/ritonavir (ABT-378/R) results in a clinically important pharmacokinetic (PK) interaction with atazanavir (ATV) but not pravastatin (PRA) [abstract no. 1644]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 334


73. Williams PL, Currier JS, Swindells S. Joint effects of HIV-1 RNA levels and CD4+ lymphocyte cells on the risk of specific opportunistic infections. AIDS 1999; 13 (9): 1035-44


82. Perrin L, King M, Brun S, et al. Failure to achieve HIV RNA <3 copies/ml does not predict loss of virologic response to Kaletra (lopinavir/ritonavir) therapy through 3 years [poster no. 1927]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec; Chicago (IL)


102. Moyle G. Use of HIV protease inhibitors as pharmacoeffect enhancers. The AIDS Reader 2001; 11 (2): 87-98


105. Dragsted UB, Gerstj J, Youle M. The interim analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir (400/100mg bid) versus saquinavir/ritonavir (1000/100mg bid) in adult HIV-1 infection: The MaxCmin trial [poster no. PL-14.5]. 6th International Congress on Drug Therapy in HIV Infection; 2002 Jul 17-21; Glasgow


145. van Heeswijk R, Cardiello P, Monhaphol T, et al. Once-daily dosing of 1,600 mg saquinavir (soft-gelatin capsules; SQV-SCG) plus low dose ritonavir (RTV, 100 mg) in HIV-1-infected Thai patients: pharmacokinetics (PK) and clinical experience (HIV-NAT 001.3) [abstract]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy; 2001 Apr 2-4; Noordwijk


150. Casado JL, Moreno A, Marti-Belda P, et al. Increased indinavir levels using twice daily ritonavir/indinavir at 100/800mg improves virological response even after multiple failure [abstract no. 1170]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 301

Correspondence: Risto S. Cvetkovic, Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.
E-mail: demail@adis.co.nz